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DEFINITIONS OF ABBREVIATIONS AND TERM S USED IN TH IS PUBLICATION
ACIP Immunization Practices Advisory Committee
AID S Acquired immunodeficiency syndrome
CD C Centers for Disease Control
CN S Central nervous system
C R S Congenital rubella syndrome
GBS Guillain-Barré syndrome
H Hemagglutinin
HB Hepatitis B
HBIG Hepatitis B immune globulin
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
HDCV Human diploid cell rabies vaccine
HRIG Human rabies immune globulin
ID Intradermal, intradermally
IG Immune globulin
IM Intramuscular, intramuscularly
IPV Inactivated poliovirus vaccine
MMR Measles, mumps, rubella vaccine
N Neuraminidase
OPV Oral poliovirus vaccine
SC Subcutaneous, subcutaneously
Td Tetanus and diphtheria combined toxoids (for adult use)
TIG Tetanus immune globulin
VZIG Varicella-zoster immune globulin
WHO World Health Organization
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This s tatem ent on adult im m unization is a supplement to the "General Recommendations 
on Im m unizations" o f the Im m unization Practices Advisory Com m ittee I.ACIP') (1). It presents 
an overview  o f im m unizations fo r adults and makes specific im m unization recommendations. 
The statem ent provides in form ation on vaccine-preventable diseases; indications fo r use o f  
vaccines, toxoids, and immune globulins recommended fo r adults; and specific side effects, 
adverse reactions, precautions, and contraindications associated w ith  use o f  these im m uno­
biologies. I t  also gives im m unization recommendations fo r adults in specific age groups and fo r  
those who have special im m unization requirements because o f  occupation, lifestyle, travel, 
environm ental situations, and health status.
This statem ent, a compendium o f ACIP recommendations, w ill not be updated regularly. 
The ACIP periodically reviews individual im m unization statements, and revised statem ents  
are published in the MMWR. The reader m ust use the detailed, up-to-date individual s ta te ­
m ents in conjunction w ith  th is compendium in order to keep abreast o f current information.
IN TRO D U CTIO N
In general, immunization policies have been directed towards vaccinating infants, children, 
and adolescents. While immunization is a routine measure in pediatric practice, it is not usually 
routine in the practice of physicians who treat adults.
The widespread and successful implementation of childhood immunization programs has 
greatly reduced the occurrence of many vaccine-preventable diseases. However, successful 
childhood immunization alone will not necessarily eliminate specific disease problems. A sub­
stantial proportion of the remaining morbidity and mortality from vaccine-preventable dis­
eases now occurs in older adolescents and adults. Persons who escaped natural infection or 
were not immunized with vaccines and toxoids against diphtheria, tetanus, measles, mumps, 
rubella, and poliomyelitis may be at risk of these diseases and their complications.
To reduce further the unnecessary occurrence of these vaccine-preventable diseases, all 
those who provide health care to older adolescents and adults should provide immunizations 
as a routine part of their practice. In addition, the epidemiology of other vaccine-preventable 
diseases (e.g., hepatitis B, rabies, influenza, and pneumococcal disease) indicates that indi­
viduals in certain age, occupational, environmental, and lifestyle groups and individuals who 
have special health problems are at increased risk of these illnesses and should be immunized. 
Travelers to some countries may be at increased risk of exposure to vaccine-preventable ill­
nesses. Finally, foreign students, immigrants, and refugees may be susceptible to these 
diseases.
A  systematic approach to immunization is necessary to ensure that every adult is appropri­
ately protected against vaccine-preventable diseases. Every visit by an adult to a health-care 
provider should be an opportunity to provide this protection. Several factors need to be con­
sidered before any patient is vaccinated. These include the susceptibility of the patient, the 
risk of exposure to the disease, the risk from the disease, and the benefits and risks from the 
immunizing agent. Physicians should maintain detailed information about previous vaccina­
tions received by each individual, including type of vaccination, date of receipt, and adverse 
events, if any, following vaccination. Information should also include the person's history of 
vaccine-preventable illnesses, occupation, and lifestyle. Vaccine histories ideally should be 
based on written documentation to ascertain whether vaccines and toxoids were administered 
at appropriate ages and at proper intervals. Close attention to factors such as military service 
and age may be helpful in determining whether any vaccines or toxoids are advisable for an in­
dividual. After the administration of any immunobiologic, the patient should be given written 
documentation of its receipt and information on which vaccines or toxoids will be needed in
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the future. For this purpose an immunization record form such as the suggested form found in 
Appendix 1 should be used routinely.
The patient or responsible person should be given information on the risks of immunobio­
logies as well as their major benefits in preventing disease both in individuals and in the com ­
munity. No formal, legally acceptable statement has been universally adopted for the private 
medical sector. Thus, the ACIP recommends that there be ample opportunity for questions 
before each immunization. CD C has developed "Important Information Statements" for use 
with federally purchased vaccines given in public health clinics. Practitioners may wish to con­
sider these or similar materials for patients. Examples of "Important Information Statements" 
can be obtained from state and many local health departments.
Modern immunobiologies are extremely safe and effective, but not completely so. All im­
munobiologies have had adverse events reported after administration. These range from fre­
quent, minor, local reactions to extremely rare, severe systemic illness, such as paralysis asso­
ciated with oral poliovirus vaccine (OPV). It is frequently impossible to establish cause- 
and-effect relationships when untoward events occur after vaccination since temporal associ­
ation alone does not necessarily indicate causation. To improve knowledge about adverse 
reactions, all temporally associated events severe enough to require the recipient to seek 
medical attention should be evaluated and reported in detail to local or state health officials 
and to the manufacturer of the immunobiologic.
General immunization considerations and recommendations are found in the ACIP state­
ment "General Recommendations on Immunization" ( 1).
The following recommendations apply generally to individuals in the indicated groups. For 
more detailed information on immunobiologies, including indications, side effects, adverse 
reactions, precautions, contraindications, dosage, and route of administration, providers are 
urged to refer to the following section on individual immunobiologies, the ACIP statements on 
specific immunobiologies (Appendix 2), and the tables and appendices at the back of this sup­
plement. Appendix 3 provides a list of vaccines, toxoids, and immune globulins available in 
the United States as of June 1 984.
Age Groups
The following text and Table 1 summarize the vaccines and toxoids recommended for 
most adults in the specific age groups. The reader is referred to the section on specific immu­
nobiologies for essential information.
A d u lts  1 8 -2 4  Years Old
All young adults should complete a primary series of diphtheria and tetanus toxoids. A pri­
mary series for adults is three doses of preparations containing tetanus and diphtheria 
toxoids, with the first two doses given at least 4 weeks apart and the third dose given 6-12  
months after the second. Those who have completed a primary series should receive a boos­
ter dose every 10 years. There is no need to repeat doses when the series schedule is 
delayed. The combined tetanus-diphtheria toxoids for adult use, Td, should be used to en­
hance protection against both diseases. Persons with unknown or uncertain histories of re­
ceiving tetanus or diphtheria toxoids should be considered unimmunized and should receive a 
full three-dose primary series of Td.
Young adults should also be immune to measles, rubella, and mumps. Persons are consid­
ered immune to measles and mumps if they have a dated record of vaccination with live vac­
cines on or after their first birthday, documentation of physician-diagnosed disease, or labora­
tory evidence of immunity. Persons vaccinated in the period 1 9 6 3 -1 9 6 7  with inactivated-
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measles-virus vaccine or with a measles vaccine of unknown type should be revaccinated 
with live-measles-virus vaccine to prevent measles disease or atypical measles syndrome if 
exposed to wild measles virus. Persons are considered immune to rubella only if they have a 
record of vaccination with rubella vaccine on or after their first birthday or laboratory evidence 
of immunity. The combined measles, mumps, rubella (MMR) vaccine is the vaccine of choice 
if recipients are likely to be susceptible to more than one of the three diseases. Persons lacking 
adequate documentation as noted above should be vaccinated.
A d u lts  2 5 -6 4  Years Old
All adults 2 5 -6 4  years of age should complete a primary series of tetanus and diphtheria 
toxoids. A primary series for adults is three doses of preparations containing tetanus and 
diphtheria toxoids, with the first two doses given at least 4 weeks apart and the third dose 
given 6-1 2 months after the second. Those who have completed a primary series should re­
ceive a booster dose every 10 years. The combined toxoids for adult use, Td, should be used 
to enhance protection against both diseases. Persons with unknown or uncertain histories of 
receiving tetanus or diphtheria toxoids should be considered unimmunized and should receive 
a full three-dose primary series of Td.
Adults born in 1957 or later should receive measles vaccine unless they have a dated 
record of vaccination with live-measles vaccine on or after their first birthday, documentation 
of physician-diagnosed disease, or laboratory evidence of immunity. Adults born before 
1 957 can be considered immune to measles, since measles was a universal infection before 
measles vaccine became available. While most adults are likely to have been infected naturally 
with mumps, mumps vaccine may be given to adults, especially males, who are considered 
susceptible. Unless proof of vaccination with rubella vaccine or laboratory evidence of im­
munity is available, rubella vaccine is recommended for women of childbearing age and for 
other adults who may find themselves in places where rubella transmission is likely to occur, 
such as hospitals, all types of schools, and other places where young people are likely to con­
gregate. The combined MMR vaccine is the vaccine of choice if recipients are likely to be sus­
ceptible to more than one of these three diseases.
A d u lts  6 5  Years O ld or O lder
All older adults should complete a primary series of tetanus and diphtheria toxoids. A  pri­
mary series for adults is three doses of preparations containing tetanus and diphtheria 
toxoids, with the first two doses given at least 4 weeks apart and the third dose given 6-1 2 
months after the second. Those who have completed a primary series should receive a boos­
ter dose every 10 years. The combined toxoids for adult use, Td, should be used to enhance 
protection against both diseases. Persons with unknown or uncertain histories of receiving 
tetanus or diphtheria toxoids should be considered unimmunized and should receive a full 
three-dose primary series of Td
All older adults should receive influenza vaccine annually. They should also receive a single 
dose of pneumococcal polysaccharide vaccine.
Special Occupations
Persons in specific occupations may be at increased risk of exposure to certain vaccine- 
preventable illnesses. Such persons may need selected vaccines and toxoids in addition to 
those routinely recommended for their age group. Table 2 provides a summary of immunobio­
logies recommended for various special occupational groups. The reader is referred to the 
section on specific immunobiologies for essential information.
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H e a lth -R e la te d  O ccupations
Medical, dental, laboratory, and other support personnel who may have contact with blood 
or blood products should be immune to hepatitis B virus (HBV) infection. The groups at high­
est risk for acquiring HBV infection and for whom HB vaccine is recommended include medical 
technicians, operating room staff, phlebotomists, physicians (particularly surgeons and pa­
thologists), nurses (particularly intravenous-therapy nurses and nurses on oncology and dialy­
sis units), dentists and oral surgeons, laboratory and blood-bank technicians, and emergency- 
room staff. Morticians and their assistants who have routine contact with blood and secre­
tions are also at high risk of HBV infection. Selected staff of institutions for the mentally 
retarded may be at increased risk of HBV infection because of exposure to bites and contact 
with skin lesions, saliva, and other potentially infected secretions in addition to blood.
Among health-care personnel with frequent exposure to blood, the prevalence of serologic 
evidence of HBV infection is estimated to range between 10% and 30%. Since the cost effec­
tiveness of serologic screening to detect susceptible individuals among health-care personnel 
depends on the prevalence of infection, each institution must decide whether serologic 
screening is cost effective. Vaccination of individuals who already have antibodies to HBV has 
not been shown to cause adverse effects.
The duration of protection from a three-dose series of HB vaccine or the need for booster 
doses has not yet been determined.
Transmission of rubella in health facilities (hospitals, physician or dentist offices, clinics, 
etc.) can disrupt hospital or office routines and cause considerable expense. Although no 
cases of congenital rubella syndrome (CRS) have been reported in association with rubella 
transmission in health facilities, therapeutic abortions have been sought by pregnant staff 
members following rubella infection (2). To prevent such situations, all medical, dental, 
laboratory, and other support health personnel, both male and female, who might be at risk of 
exposure to patients infected with rubella, or who might have contact with pregnant patients, 
should be immune. Rubella vaccine is recommended for all such personnel unless they have 
either proof of vaccination with rubella vaccine on or after their first birthday or laboratory evi­
dence of immunity. Combined MMR vaccine is the vaccine of choice if recipients are likely to 
be susceptible to measles and/or mumps as well as to rubella.
Measles transmission in health facilities can also be disruptive and costly. To prevent such 
situations, all health personnel born in 1957 or later who may have contact with patients in­
fected with measles should be immune. Such persons can be considered immune only if they 
have documentation of having received live-measles vaccine on or after their first birthday, a 
record of physician-diagnosed measles, or laboratory evidence of immunity. Measles vaccine 
is recommended for all persons lacking such documentation. Combined MMR vaccine is the 
vaccine of choice if recipients are likely to be susceptible to rubella and/or mumps as well as 
to measles. Adults born before 1957 can be considered immune to measles since measles 
w as a universal infection before the availability of measles vaccine.
Poliovirus vaccine is not routinely recommended for persons older than high school age 
(18-19 years old). However, hospital personnel having close contact with patients who may 
be excreting wild polioviruses, and laboratory personnel handling specimens that may contain 
wild polioviruses, should have completed a primary series of poliovirus vaccine. For personnel 
who do not have proof of having completed a primary series, completion is recommended 
with inactivated poliovirus vaccine (IPV). IPV is preferred because there is a slightly increased 
risk in adults of vaccine-associated paralysis following receipt of OPV. In addition, since vac­
cine poliovirus may be excreted by OPV recipients for 30 or more days, the use of OPV in­
creases the risk of acquiring vaccine-associated paralytic poliomyelitis among susceptible im­
munocompromised contacts and susceptible close contacts of OPV recipients.
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Smallpox vaccination is indicated only for laboratory workers involved with orthopox 
viruses or in producing and testing smallpox vaccine. When indicated, smallpox vaccination 
should be given at least every 3 years.
Plague vaccine is indicated for laboratory personnel working with Yersinia pestis  possibly 
resistant to antimicrobial agents and for persons performing Y. pestis  aerosol experiments.
Preexposure rabies vaccination is indicated for laboratory workers directly involved with 
testing or isolating rabies virus.
Veterinarians and A n im a l H andlers
Veterinarians and animal handlers are at risk of rabies exposure because of occupational 
contact with both domestic and wild animals. They should receive preexposure rabies-vaccine 
prophylaxis with human diploid cell rabies vaccine (HDCV). Preexposure vaccination against 
rabies does not eliminate the need for additional therapy after exposure to rabies; it does, 
however, simplify postexposure therapy by eliminating the need for human rabies immune 
globulin (HRIG) and by decreasing the number of postexposure doses of vaccine needed. Per­
sons at continued risk of frequent exposure should receive a booster dose of HDCV every 2 
years or have their serum tested for rabies antibody every 2 years and, if the titer is inadequate 
( <  5 by the rapid fluorescent-focus inhibition test), receive a booster dose.
S e le c te d  F ie ld  Person n e l
Plague vaccine is indicated for field personnel who cannot avoid regular exposure to poten­
tially plague-infected wild rodents and rabbits and their fleas.
Preexposure rabies vaccine prophylaxis should be considered for field personnel who are 
likely to have contact with potentially rabid dogs, cats, skunks, raccoons, bats, or other wild­
life species.
Se w a g e  W orkers
Sewage workers, as all other adults, should be adequately vaccinated against diphtheria 
and tetanus.
Poliovirus and typhoid vaccines and immune globulin are not routinely recommended for 
sewage workers.
Lifestyles
Various lifestyles may increase the risk of exposure to certain vaccine-preventable ill­
nesses. Persons with these lifestyles may require vaccines in addition to those routinely 
recommended for their age group. Table 2 provides a summary of the vaccines 
recommended.
H o m o se x u a lly  A c t iv e  M ales
Homosexually active males are at high risk of HBV infection. Between 35% and 80°o have 
serologic evidence of HBV infection. Susceptible homosexual males should be vaccinated 
with HB vaccine as early as possible after they begin homosexual activity because they can be 
expected to acquire HBV infection at a rate of 10%-20% per year. The duration of protection 
from a three-dose series of HB vaccine and the need for booster doses have not yet been 
determined. Because of the high prevalence of infection, prevaccination serologic screening 
of homosexual males may be cost effective regardless of their age or of how long they have 
been homosexually active.
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U sers o f  I ll ic it  In jecta b le  Drugs
Users of illicit injectable drugs are at high risk of HBV infection. Serologic evidence of HBV 
infection has been found in 60% -80%  of these individuals. Efforts should be made to vaccinate 
susceptible users with HB vaccine as early as possible after their drug use begins because 
they can be expected to acquire HBV infection at a rate of 10%-20% per year. The duration of 
protection from a three-dose series of HB vaccine and the need for booster doses have not 
yet been determined Because of the high prevalence of infection, prevaccination serologic 
screening of users of illicit injectable drugs to avoid unnecessary immunization is cost 
effective.
These drug users are also at increased risk of tetanus, and their tetanus immunization 
status should be kept up to date with Td.
Environmental Situations
Certain environments may place an individual at increased risk of certain vaccine- 
preventable diseases. Table 2 summarizes additional vaccines recommended for persons in 
selected environments. The reader is referred to the section on specific immunobiologies for 
essential information.
In m a tes o f  Lo n g - Term C o rrectio n a l F a c ilit ie s
Serologic evidence of HBV infection has been found in 10%-80% of male prisoners. A l­
though the frequency of transmission during imprisonment has not been documented, the en­
vironment of long-term correctional facilities may be associated with a high risk of transmis­
sion of HBV infection because of the frequency of use of illicit injectable drugs and of homo­
sexual behavior. In selected long-term institutional settings, prison officials may elect to un­
dertake serologic HBV screening and vaccination programs. The duration of protection from a 
three-dose series of HB vaccine and the need for booster doses have not yet been determined.
R e s id e n ts  o f  In stitu tio n s fo r the M e n ta lly  R e ta rd ed
Institutions for the mentally retarded provide a setting conducive to the transmission of 
HBV infection through bites and contact with blood, skin lesions, saliva, and other potentially 
infectious secretions. Serologic evidence of HBV infection has been found in 35% -80%  of resi­
dents of such institutions. New admissions to these institutions should be vaccinated as soon 
as possible. For current residents, screening and vaccination of susceptible residents is recom­
mended. Because of the high prevalence of infection, preimmunization serologic screening of 
those already institutionalized may be cost effective; however, screening of new admissions 
very likely will not be. Residents of group homes, foster homes, and similar settings who have 
household contact with a carrier of HBV should also be vaccinated. The duration of protection 
from a three-dose series of HB vaccine and the need for booster doses have not yet been 
determined.
Travel
The risk of acquiring illness during international travel depends on the areas of the world to 
be visited and the extent to which the traveler is likely to be exposed to vaccine-preventable 
diseases. When considering travel, people often seek advice from health-care personnel on 
immunization. This provides a good opportunity to review the person's immunization status 
and administer primary series or booster doses, if needed.
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In most countries, measles, mumps, and rubella remain uncontrolled. Therefore, the risk of 
acquiring these diseases while traveling outside the United States is greater than the risk in­
curred within the United States. Approximately 50S, of imported measles cases reported for 
1 980-1 983 occurred in citizens returning to the United States (3). To minimize importations 
by U.S. citizens, all travelers born in 1 957 or later should be immune to measles. Women trav­
elers of childbearing ages should be immune to rubella before leaving the United States.
In developed countries such as Japan, Canada, Australia, New Zealand, and the European 
countries, the risk of acquiring other vaccine-preventable diseases such as poliomyelitis, 
diphtheria, and tetanus is usually no greater than the risk incurred while traveling in the United 
States. In contrast, travelers to developing countries are, in general, at increased risk of expo­
sure to many infections, including wild polioviruses and diphtheria. Accordingly, such travelers 
should be immune to poliomyelitis and diphtheria, in particular.
For protection against poliomyelitis, unimmunized adults should receive at least two doses 
of IPV 1 month apart, and preferably a complete primary series, before traveling to a develop­
ing country. If an individual's travel plans do not permit this interval, then a single dose of OPV 
is recommended. For adults previously incompletely immunized with OPV or IPV, the remain­
ing doses of either vaccine required for completion of the primary series should be given, 
regardless of the interval since the last dose or the type of vaccine previously received. A 
single additional dose of either OPV or IPV should be given to travelers who have previously 
completed a primary series of OPV or IPV
Selective immunization of travelers with vaccines against yellow fever, cholera, typhoid, 
plague, meningococcal disease, rabies, or HBV infection or administration of immune globulin 
(IG) to prevent hepatitis A is recommended on the basis of known, or perceived, disease- 
specific risks in the country(ies) to be visited and the type and duration of travel within a coun­
try. In the instances of cholera and yellow fever, vaccination requirements may have been es­
tablished by the country to be visited. Countries currently reporting yellow fever, cholera, and 
plague are identified biweekly in the Sum m ary o f Health Inform ation fo r  International Travel. 
and information on known or probably infected areas is published annually in Health Inform a­
tion fo r International Travel, which also lists specific requirements for cholera and yellow 
fever vaccinations for each country. All state health departments and many county and city 
health departments receive both publications. For entry into countries requiring yellow fever 
or cholera vaccination, travelers must have an International Certificate of Vaccination validat­
ed by an appropriate authority. State or local health departments can provide the addresses 
of persons or centers able to validate certificates.
More information on specific vaccine-preventable illnesses that a traveler might encounter 
is provided in the sections describing specific vaccines.
Foreign Students, Immigrants, and Refugees
In many countries children and adolescents are not routinely immunized against diphtheria, 
tetanus, measles, mumps, rubella, and poliomyelitis. A s a result, persons entering the United 
States to pursue college and postgraduate studies or as immigrants or refugees may be su s­
ceptible to one or more of these diseases.
Unless foreign students, immigrants, and refugees can provide a vaccination record docu­
menting the receipt of recommended vaccines or toxoids at appropriate ages and intervals or 
laboratory evidence of immunity, they should receive the appropriate vaccines for their age as 
noted in age-specific recommendations (see page 2S) and in Table 1. Poliovirus vaccines are 
not recommended, in general, for persons 1 8 years of age or older.
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Special Health Status
Som e vaccines may be contraindicated for persons with certain health problems; other 
vaccines may be indicated because of an underlying health condition. Table 3 provides a sum ­
mary of immunobiologies indicated or contraindicated for persons with selected health 
problems.
P re g n a n cy
When any vaccine or toxoid is to be given during pregnancy, waiting until the second or 
third trimester, when possible, is a reasonable precaution to minimize concern about possible 
teratogenicity.
Pregnant women not vaccinated previously against tetanus and diphtheria should receive 
two doses of Td properly spaced. Those who have previously received one or two doses of 
tetanus or diphtheria toxoid should complete their primary series during pregnancy. A primary 
series is three doses of preparations containing tetanus and diphtheria toxoids, with the first 
two doses given at least 4 weeks apart and the third dose given 6 -12  months after the 
second. Pregnant women who have completed a primary series should receive a booster dose 
of Td if 10 or more years have elapsed since their last dose.
Because of a theoretical risk to the developing fetus, live-virus vaccines should not usually 
be given to pregnant women or to those likely to become pregnant within 3 months. If, how­
ever, immediate protection against poliomyelitis or yellow fever is needed because of immi­
nent exposure, OPV or yellow fever vaccine may be given. If the only reason to vaccinate a 
pregnant woman with yellow fever vaccine is an international travel requirement, efforts 
should be made to obtain a waiver letter (see page 1 9S).
It is strongly recommended that rubella vaccine be administered in the postpartum period 
to women not known to be immune, preferably before discharge from the hospital.
Information about immunobiologies and vaccine-preventable diseases during pregnancy is 
summarized in Appendix 4.
C o n d itio n s That C o m p ro m ise  the Im m une S y ste m
Persons with conditions that compromise their immune responses (e.g., leukemia, lympho­
ma, and generalized malignancy or immunosuppressive therapies) should receive annual in­
fluenza vaccination with the currently formulated vaccine. Persons with conditions associated 
with increased risk of pneumococcal disease or its complications should receive a single dose 
of pneumococcal polysaccharide vaccine. The effectiveness of these vaccines in such per­
sons may be limited, but the risk of disease is substantial and adverse reactions are minimal.
In general, live-virus vaccines should not be given to persons who are immunocompro­
mised as a result of immune deficiency diseases, leukemia, lymphoma, or generalized 
malignancy or are immunosuppressed as a result of therapy with corticosteroids, alkylating 
drugs, antimetabolites, or radiation. However, susceptible patients with leukemia in remission 
who have not had chemotherapy for at least 3 months may receive live-virus vaccines. The 
exact interval between discontinuing immunosuppressives and regaining the ability to respond 
to individual vaccines is not known. Estimates of experts vary from 3 months to 1 year.
Short-term (less than 2 weeks) corticosteroid therapy, topical steroid therapy (e.g., nasal 
or skin), and intraarticular, bursal, or tendon injections with corticosteroids should not be im­
munosuppressive and do not necessarily contraindicate vaccination with live-virus vaccines. 
Vaccination should be avoided if systemic immunosuppressive levels are achieved by topical 
application.
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H e m o d ia ly sis
Persons receiving hemodialysis have been at high risk of infection with HBV, although envi­
ronmental control measures have reduced this risk during the past few years. Nationwide, an 
estimated 1 5% of hemodialysis patients have serologic evidence of HBV infection, and routine 
serologic screening of hemodialysis patients is currently recommended. Susceptible patients 
who will soon require or are currently receiving long-term hemodialysis should receive three 
double doses of HB vaccine as soon as possible. Double the normal dose is recommended for 
these patients because of lower vaccine immunogenicity in this group. Postvaccination 
screening to demonstrate antibody to hepatitis B surface antigen (HBsAg) is recommended in 
this group. Approximately 60% of hemodialysis patients who receive double doses of HB vac­
cine demonstrate antibodies against HBV. The duration of protection from a three-dose series 
of HB vaccine and the need for booster doses have not yet been determined.
Because persons with chronic renal disease are at increased risk of adverse consequences 
from infections of the lower respiratory tract, hemodialysis patients should receive annual in­
fluenza vaccination with the current formulated vaccine. These patients are also at increased 
risk of developing pneumococcal infection, as well as of experiencing more severe pneumo­
coccal disease, and should receive pneumococcal polysaccharide vaccine.
S p le n ic  D ysfu n ctio n  or A n a to m ic A sp le n ia
Persons with splenic dysfunction or anatomic asplenia are known to be at increased risk of 
contracting fatal pneumococcal bacteremia and should receive pneumococcal polysaccharide 
vaccine. Persons scheduled for elective splenectomy should receive pneumococcal polysac­
charide vaccine at least 2 weeks before the operation.
F a c to r  V III a nd  I X  D e fic ie n c ie s
Patients with clotting disorders who receive factor VIII or IX concentrates have an in­
creased risk of HBV infection. Vaccination with HB vaccine is recommended for susceptible 
patients. The degree and duration of protection from a three-dose series of HB vaccine and 
the need for booster doses have not yet been determined.
Prevaccination serologic screening for HBV markers is recommended for patients who 
have already received multiple infusions of these products.
Ch ro nic  A lco h o lism
Persons with chronic alcoholism may be at increased risk of contracting a pneumococcal 
infection or having a more severe pneumococcal illness. Such persons, especially those with 
cirrhosis, should receive pneumococcal polysaccharide vaccine.
H ig h -R isk  D ise a se s
Persons with disease conditions that increase the risk of adverse consequences from 
lower-respiratory-tract infections should receive annual influenza vaccination with the current 
formulated vaccine. These conditions include:
(a) Acquired or congenital heart disease with actual or potentially altered circulatory 
dynamics.
(b) Any chronic disorder or condition that compromises pulmonary function.
(c) Diabetes mellitus or other metabolic diseases that increase the likelihood that infections 
will be more severe than for persons without such conditions.
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(d) Chronic renal disease with azotemia or nephrotic syndrome.
(e) Chronic, severe anemia, such as sickle cell disease.
Som e chronic illnesses (e.g., chronic pulmonary disease, congestive heart failure, diabetes 
mellitis) predispose individuals to an increased risk of pneumococcal illness or its complica­
tions. While data on the effectiveness of pneumococcal polysaccharide vaccine for chronical­
ly ill persons are not conclusive, such persons should receive the vaccine.
V A C C IN E-P R EV EN TA B LE D IS E A S E S  AND TH EIR  
IM MU NOBIOLOG ICS
Vaccines, toxoids, and immune globulins are available for use in the prevention of a 
number of diseases. These diseases and their specific immunobiologies are presented in this 
section. For each immunobiologic, dosage, route of delivery, indications for use, side effects, 
adverse reactions, precautions, and contraindications to be considered before administration 
are described here and are summarized in Table 4.
Toxoids
D iphtheria
The occurrence of diphtheria has decreased dramatically in the United States, largely be­
cause of the widespread use of diphtheria toxoid. Only 11 cases of diphtheria were reported 
in the period 1 9 8 0 -1 9 8 2 . From 1977 through 1982, 56% of the 34 reported cases of re­
spiratory diphtheria occurred in adults 20  years of age or older, and 24% of the cases o c­
curred in adults 50 years of age or older. The age distribution for persons who died from 
diphtheria was similar. Diphtheria occurs primarily among unimmunized or inadequately 
immunized individuals. Limited serosurveys done since 1977 indicated that 62% of adults 
1 8 -3 9  years of age and 41% -84%  of those 60 years of age or older lacked protective levels 
of circulating antitoxin against diphtheria (4 -6 ).
• Diphtheria toxoid
Complete and appropriately timed immunization is at least 95% effective in preventing 
diphtheria. The combined preparation Td is recommended for use in adults since a large pro­
portion of adults lack protective levels of circulating antibody against tetanus (4-6) .  Further­
more, Td contains much less diphtheria toxoid than other diphtheria toxoid-containing pro­
ducts, and as a result, reactions to the diphtheria component are less likely. Immunization with 
toxoid does not, however, prevent or eliminate carriage of Corynebacterium diphtheriae.
• Toxoid indications
All adults lacking a completed primary series of tetanus and diphtheria toxoids should 
complete the series with Td. A primary series for adults is three doses of preparations con­
taining tetanus and diphtheria toxoids, with the first two doses given at least 4 weeks apart 
and the third dose given 6-1 2 months after the second. All adults for whom 10 years or more 
have elapsed since completion of their primary series or since their last booster dose should 
receive a dose of Td. Thereafter, a booster dose of Td should be administered every 1 0 years. 
There is no need to repeat doses if the schedule for the primary series or booster doses is 
delayed. (For toxoid side effects and adverse reactions, and precautions and contraindications, 
see page 1 2S).
Tetanus
The occurrence of tetanus has decreased dramatically, largely because of the widespread 
use of tetanus toxoid. Nevertheless, the number of cases remained relatively constant from
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1 973 through 1 982, averaging 88 reported cases per year. Tetanus occurs almost exclusive­
ly in unimmunized or inadequately immunized individuals. Immune pregnant women confer 
temporary protection against tetanus to their infants through transplacental maternal anti­
body. In the period 1 977-1 982, persons 20 years of age or older accounted for 89% of the 
504 reported tetanus cases for which patient ages were known; persons 60 years of age or 
older accounted for 55%. The age distribution of persons who died from tetanus was similar. 
Serosurveys done since 1977 indicated that 110/- of adults 1 8 -3 9  years of age and 49° j-66% 
of those 60 years of age or older lacked protective levels of circulating antitoxin against 
tetanus (4-6) .
• Tetanus toxoid
Complete and appropriately timed immunization is nearly 100% effective in preventing 
tetanus. The combined preparation, Td, is the preferred preparation for active tetanus immuni­
zation of adults since a large proportion of adults lack protective levels of circulating antitoxin 
against diphtheria (4-6) .
• Toxoid indications
All adults lacking a complete primary series of tetanus and diphtheria toxoids should com ­
plete the series with Td. A primary series for adults is three doses of preparations containing 
tetanus and diphtheria toxoids, with the first two doses given at least 4 weeks apart and the 
third dose given 6 -12  months after the second. All adults for whom 10 years or more have 
elapsed since completion of their primary series or since their last booster dose should receive 
a booster dose of Td. Thereafter, a booster dose of Td should be administered every 10 
years. There is no need to repeat doses if the primary schedule for the series or booster doses 
is delayed.
The recommended pediatric schedule for DTP vaccine includes a booster dose at age 4-6 
years. The first Td booster is recommended at age 14-1 6 years (10 years after the dose at 
age 4 -6  years). One means of ensuring that persons continue to receive boosters every 10 
years is to vaccinate persons routinely at mid-decade ages, e.g., 25 years, 35 years, etc.
For wound management the need for active immunization, with or without passive immuni­
zation, depends on the condition of the wound and the patient's immunization history. A  sum­
mary of the indications for active and passive immunization is provided in Table 5. Only rarely 
have cases of tetanus occurred in persons with a documented primary series of toxoid 
injections.
Evidence indicates that complete primary immunization with tetanus toxoid provides long- 
lasting protection— 10 years or more in most recipients. Consequently, after complete primary 
tetanus immunization, boosters are recommended at 10-year intervals. For clean and minor 
wounds occurring during the 10-year interval no additional booster is recommended. For 
other wounds, a booster is appropriate if the patient has not received tetanus toxoid within 
the preceding 5 years. Antitoxin antibodies develop rapidly in persons who have previously re­
ceived at least two doses of tetanus toxoid.
Persons who have not completed a full primary series of injections or whose immunization 
status is unknown or uncertain may require tetanus toxoid and passive immunization at the 
time of wound cleaning and debridement. It is not sufficient to ascertain the interval since the 
most recent toxoid dose. A  careful attempt should be made to determine whether a patient 
has previously completed primary immunization and, if not, how many doses have been 
given. Persons with unknown or uncertain previous immunization histories should be consid­
ered to have had no previous tetanus toxoid doses.
Td is the preferred preparation for active tetanus immunization in managing the wounds of 
adults. Td is used to enhance protection against diphtheria concurrently, since a large propor­
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tion of adults are susceptible. Thus, if advantage is taken of visits for care of acute health 
problems, such as for wound management, some patients who otherwise would remain sus­
ceptible can be protected against both diseases. Primary immunization should ultimately be 
completed for persons documented to have received fewer than the recommended number 
of doses, including doses given as part of wound management.
If passive immunization is needed, human tetanus immune globulin (TIG) is the product of 
choice. The currently recommended prophylactic dose of TIG for wounds of average severity 
is 25 0  units, intramuscularly (IM). When tetanus toxoid and TIG are given concurrently, separ­
ate syringes and separate sites should be used. Most experts consider the use of adsorbed 
toxoid mandatory in this situation.
Toxoid  (Td) S id e  E ffe c t s  and A d v e rse  R e a ctio n s
Local reactions, generally erythema and induration with or without tenderness, can occur 
after the administration of Td. Fever and other systemic symptoms are less common.
Arthus-type hypersensitivity reactions characterized by severe local reactions generally 
starting 2-8 hours after an injection and often associated with fever and malaise may occur, 
particularly in persons who have received multiple boosters of tetanus toxoid.
Rarely, severe systemic reactions such as generalized urticaria, anaphylaxis, or neurologic 
complications have been reported after administration of tetanus and diphtheria toxoids. 
Peripheral neuropathy has been reported rarely after administration of tetanus toxoid, al­
though a causal relationship has not been established.
To xo id  (Td) P re ca u tio n s and C o n tra in d ica tio n s
Although there is no evidence that tetanus and diphtheria toxoids are teratogenic, waiting 
until the second trimester of pregnancy to administer Td is a reasonable precaution to mini­
mize any concern over teratogenicity.
A  history of a neurologic reaction or a severe hypersensitivity reaction (e.g., generalized ur­
ticaria or anaphylaxis) following a previous dose is a contraindication to tetanus and diphtheria 
toxoids. Local side effects alone do not preclude continued use. If a prior systemic reaction is 
suspected of representing allergic hypersensitivity, appropriate skin testing to document im­
mediate hypersensitivity may be useful before tetanus toxoid immunization is discontinued (7). 
Mild, nonspecific skin-test reactivity to tetanus toxoid is common. Most vaccinees develop 
cutaneous delayed hypersensitivity to the toxoid.
Persons experiencing severe Arthus-type hypersensitivity reactions to a prior dose of 
tetanus toxoid usually have very high serum tetanus antitoxin levels and should not be given 
even emergency booster doses of Td more frequently than every 10 years.
Although a minor illness, such as a mild upper-respiratory infection, should not be cause 
for postponing vaccination, a severe febrile illness is reason to defer routine vaccination.
Live-Virus Vaccines
M e a sle s
In 1983, only 5.6% of the 3 ,139 counties in the United States reported cases of measles. 
Indigenous transmission of measles has been eliminated from most of the United States be­
cause of widespread vaccination. However, importations of disease are frequent (more than 
1 0 0  each year), and there is a continued risk of exposure, particularly for young adults attend­
ing college or universities or traveling abroad.
In 1982, 1 1.7% of measles patients whose ages were reported were 20 years of age or 
older. Outbreaks continue to occur in universities and colleges and other places where young
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adults congregate. In the first half of 1983, 51% of reported cases were among college stu­
dents or were epidemiologically linked to campus outbreaks. It is estimated that as many as 
20% of young adults lack detectable antibody and may be susceptible to measles.
Encephalitis or death follows measles disease in approximately one case per 1,000. The 
risk of encephalitis is greatest in adult patients. Aside from infants, the highest measles case- 
fatality ratio occurs in adults.
Measles illness during pregnancy increases rates of spontaneous abortion, premature 
labor, and low birth weight for infants. Although cases of congenital malformation following 
measles infection during pregnancy have been reported, no consistent patterns have been 
demonstrated.
* M easles vaccine
Measles vaccine produces a mild or inapparent noncommunicable infection. A single sub­
cutaneously (SC) administered dose of live-measles vaccine provides durable protection 
against measles illness in approximately 95% of vaccinees, extending probably for their life­
time. Combined MMR vaccine is the vaccine of choice if recipients are likely to be susceptible 
to rubella and/or mumps as well as to measles. Although reactions following measles, 
mumps, and rubella vaccines in persons previously immune have been reported, evidence and 
experience overwhelmingly suggest that vaccination with MMR of persons who were pre­
viously immune to one or more of its components is not associated with significant adverse 
effects.
* Vaccine indications
Measles vaccine is indicated for all persons born in 1 957 or later who lack documentation 
of receipt of live-measles vaccine on or after their first birthday, physician-diagnosed measles, 
or laboratory evidence of immunity. Persons born before 1957 can generally be considered 
immune since measles was a universal infection before measles vaccine became available. In­
dividuals who received vaccine before their first birthday, killed-measles vaccine, killed- 
measles vaccine followed within 3 months by live-measles vaccine, or a measles vaccine of 
unknown type in the period 1 9 6 3 -1 9 6 7  should be revaccinated. An estimated 
6 0 0 ,0 0 0 -9 0 0 ,0 0 0  persons in the United States received killed-measles vaccine in the years 
19 6 3 -1 9 6 7 .
Because the risk of acquiring measles outside the United States is greater than the risk in­
curred in the United States, travelers should be immune to measles before leaving the United 
States.
Generally, young adults who are exposed to measles and who have no or uncertain docu­
mentation of live-measles vaccination on or after their first birthday, no record of physician- 
diagnosed measles, and no laboratory evidence of immunity should be vaccinated within 72 
hours after exposure, when vaccination is most likely to be protective. If the exposure did not 
result in infection, the vaccine should induce protection against subsequent measles infection. 
An acceptable alternative is to use IG, which can prevent or modify infection if administered 
within 6 days after exposure. IG is principally indicated when measles vaccine is contraindicat­
ed. IG should not be used in an attempt to control measles outbreaks. The recommended 
dose of IG is 0.25 ml/kg IM, not to exceed 1 5 ml. Live-measles vaccine should be given 3 
months after IG is administered, by which time the passive measles entibodies should have 
disappeared.
* Vaccine side effects and adverse reactions
Reactions to measles vaccine do not appear to be age related. About 5%-1 5% of vaccinees 
may develop a temperature of 103°F (39.4°C) or higher, generally beginning between days 5 
and 12 after vaccination; fever usually lasts 1-2 days and, rarely, up to 5 days. Transient
14S MMWR Septem ber 28, 1984
rashes have been reported in approximately 5% of vaccinees. The incidence rate of encephali­
tis or encephalopathy following measles vaccination is lower than the observed background 
incidence rate of encephalitis of unknown etiology and much lower than that following natural 
measles.
Reactions after live-measles vaccination occur in 4% -55%  of prior recipients of killed- 
measles vaccine. The reactions are generally mild, consisting of a local reaction with or with­
out a low-grade fever of 1-2 days' duration. Such reactions are considerably milder than 
atypical measles syndrome, an illness which may affect prior recipients of killed-measles vac­
cine who are exposed to natural measles.
• Vaccine precautions and contraindications
Vaccination should not be postponed because of a minor illness, such as a mild upper- 
respiratory infection. However, vaccination of persons with severe febrile illnesses should be 
postponed until recovery. Vaccine should be given 14 days before or deferred for at least 6 
weeks, and preferably 3 months, after a person has received IG, whole blood, or other blood 
products containing antibody.
Because of a theoretical risk to the developing fetus, measles vaccine should not be given 
to pregnant women.
Measles vaccine should not be given to persons who are immunocompromised as a result 
of immune deficiency diseases, leukemia, lymphoma, or generalized malignancy or are immu- 
nosuppressed as a result of therapy with corticosteroids, alkylating drugs, antimetabolites, or 
radiation. (See "Conditions That Compromise the Immune System," page 8S.)
There is no evidence that live-measles vaccine exacerbates tuberculosis. If tuberculin skin 
testing is needed, it should be done on the day of vaccination and read 4 8 -7 2  hours later. For 
a recent vaccinee, it is prudent to wait 4 -6  weeks after receipt of measles vaccine before ad­
ministering a tuberculin skin test since measles vaccination may temporarily suppress tubercu­
lin reactivity.
Persons with a history of any sign or symptom of an anaphylactic reaction (i.e., hives, 
swelling of the mouth and throat, difficulty in breathing, hypotension, or shock) following in­
gestion of eggs or receipt of neomycin should be given measles vaccine only with extreme 
caution. Protocols have been developed for vaccinating such persons (S). Persons with reac­
tions that are not anaphylactic are not at increased risk and can be vaccinated.
M um ps
The occurrence of reported mumps cases in the United States has decreased steadily 
since the introduction of live-mumps-virus vaccine. In 1983, a record low of 3 ,297 cases 
were reported provisionally; this number represented a 98% decline from the 1 85,691 cases 
reported in 1967, the year live-mumps vaccine was licensed. In 1982, 5 ,270 cases were 
reported, of which 9% occurred in persons 20 years of age or older.
Although mumps disease is generally self-limiting, meningeal signs may appear in up to 
1 5% of cases, and orchitis in up to 20% of clinical cases among postpubertal males. Sterility is 
a rare sequela of mumps orchitis among males. Deafness occurs at a rate of one case per 
1 5 ,0 0 0  cases of mumps.
Serologic surveys indicate that most individuals have been infected with mumps by 20 
years of age.
• Mumps vaccine
Live-mumps vaccine has been available since 1967. A single dose of live-mumps vaccine 
administered S C  provides protective and long-lasting levels of antibody in over 90% of reci­
pients. Reported clinical vaccine efficacy ranges between 75% and 90%. MMR is the vaccine
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of choice if recipients are likely to be susceptible to measles and/or rubella as well as to 
mumps. Although reactions following measles, mumps, and rubella vaccines in persons pre­
viously immune have been reported, evidence and experience overwhelmingly suggest that 
the vaccination with MMR of persons who were previously immune to one or more of its 
components is not associated with significant adverse effects.
• Vaccine indications
Mumps vaccine is indicated for all adults, particularly males, believed to be susceptible. 
Most adults are likely to have been infected naturally and generally can be considered 
immune, even if they did not have clinically recognizable mumps disease. Killed-mumps vac­
cine was available from 1 950 until 1 978. Persons who received killed-mumps vaccine might 
benefit from vaccination with live-mumps vaccine.
• Vaccine side effects and adverse reactions
Parotitis after vaccination has been reported rarely. Allergic reactions including rash, pru­
ritus, and purpura have been associated temporally with mumps vaccination but are uncom­
mon, usually mild, and of brief duration. The frequency of reported central nervous system 
(CNS) dysfunction following mumps vaccination is lower than the observed background inci­
dence rate in the general population.
• Vaccine precautions and contraindications
Vaccine should be given at least 14 days before or deferred for at least 6 weeks, and 
preferably 3 months, after a person has received IG, whole blood, or other blood products 
containing antibody.
Because of the theoretical risk of fetal damage following administration of a live-virus vac­
cine to a pregnant woman, it is prudent to avoid giving mumps vaccine to pregnant women.
Mumps vaccine should not be given to persons who are immunocompromised as a result 
of immune deficiency diseases, leukemia, lymphoma, or generalized malignancy or are immu- 
nosuppressed as a result of therapy with corticosteroids, alkylating drugs, antimetabolites, or 
radiation. (See "Conditions That Compromise the Immune System," page 8S.)
Persons with a history of any sign or symptom of an anaphylactic reaction (i.e., hives, 
swelling of the mouth and throat, difficulty in breathing, hypotension, or shock) following in­
gestion of eggs or receipt of neomycin should be vaccinated only with extreme caution. Proto­
cols have been developed for vaccinating persons with severe egg allergy (8) .  Persons with 
reactions that are not anaphylactic are not at increased risk and can be vaccinated.
R ubella
Preventing fetal infection and consequent C R S  are the objectives of rubella immunization. 
Fetal infection occurring during the first trimester of pregnancy can lead to C R S  in up to 80% 
of fetuses. In addition, fetal wastage due to miscarriage or therapeutic abortion following ma­
ternal rubella disease or exposure during the first trimester remains a frequent occurrence.
The number of reported rubella cases has decreased steadily from over 5 6 ,000  cases in 
1 969, the year rubella vaccine was licensed, to 2 ,325 cases in 1 982. In 1 982, only 11.7% of 
the 3,1 37 counties in the United States reported cases of rubella. The 1 983 provisional total 
of 95 4  cases is an all-time low. Because, until recently, many adolescents and young adults 
had not been vaccinated, decreases in incidence rates of reported rubella were observed pri­
marily for children. Recent efforts to increase delivery of vaccine to cellege-age and older per­
sons have led to the current decline in the incidence rates for these age groups. However, an 
estimated 1 0%-1 5% of young adults remain susceptible to rubella, and limited outbreaks con­
tinue to be reported in universities, colleges, and places of employment—notably hospitals.
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Vaccination of young children has prevented widespread epidemics of rubella and of C R S  
and eventually will lead to the elimination of C R S  as vaccinated cohorts enter the childbearing 
age. However, increased efforts to ensure that all women of childbearing age, in particular, are 
vaccinated will hasten the elimination of rubella and C R S  in the United States. Additional aids 
to elimination of rubella and C R S  include 1) achieving and maintaining high immunization 
levels, 2) maintaining vigorous surveillance, and 3) practicing aggressive outbreak control.
• Rubella vaccine
A single S C  administered dose of live, attenuated rubella vaccine provides long-term, 
probably lifetime, immunity in approximately 95% of vaccinees. Moreover, there is no risk to 
susceptible contacts of vaccinees. MMR is the vaccine of choice if recipients are likely to be 
susceptible to measles and/or mumps as well as to rubella. Although reactions following ad­
ministration of measles, mumps, and rubella vaccines to persons previously immune have 
been reported, evidence and experience overwhelmingly suggest that the vaccination with 
MMR of persons who are already immune to one or more of its components is not associated 
with significant adverse effects.
• Vaccine indications
Rubella vaccine is recommended for adults, particularly females, unless proof of immunity 
is available (i.e., documented rubella vaccination on or after the first birthday or a positive 
serologic test) or unless the vaccine is specifically contraindicated. In particular, nonpregnant 
susceptible women of childbearing age should be provided rubella vaccination 1) during rou­
tine internal medicine and gynecologic outpatient care, 2) during routine care in a family plan­
ning clinic, 3) following premarital screening, 4) before discharge from a hospital for any 
reason, and 5) after childbirth or abortion. Ideally, any contact with the health-care system 
should be used as an opportunity to vaccinate susceptible women. In addition, evidence of 
rubella immunity should be required for all individuals in colleges and universities. Health-care 
programs in work places and in other places where women of childbearing age congregate 
should ensure that the rubella immune status of every employee is ascertained and that rubella 
immunization is made available. All hospital personnel (male and female) who might be at risk 
of exposure to patients infected with rubella or who might have contact with pregnant pa­
tients or personnel should be immune to rubella. Consideration should be given to making 
rubella immunity a condition for employment. Finally, since the risk of acquiring rubella while 
traveling outside the United States is greater than the risk incurred within the United States, 
all women travelers, particularly those of childbearing age, should be immune before leaving 
the United States.
• Vaccine side effects and adverse reactions
Up to 40% of susceptible adult vaccinees in large-scale field trials have had joint pain, usu­
ally of the small peripheral joints, after vaccination; frank arthritis is reported infrequently. Ar­
thralgia and transient arthritis occur more frequently and tend to be more severe in susceptible 
women than in children. When joint symptoms or other types of pain and paresthesias do 
occur, they generally begin 3 -25  days after vaccination, persist for 1-11 days, and rarely 
recur. Adults with joint problems usually have not had to disrupt work activities. Complaints 
of transient peripheral neuritis such as paresthesias and pain in the arms and legs have o c­
curred very rarely and only in susceptible vaccinees.
• Vaccine precautions and contraindications
Rubella vaccine should be given at least 14 days before administration of IG or deferred 
for at least 6 weeks, and preferably 3 months, after administration. On the other hand, previ­
ous administration of whole blood or other blood products containing antibody (e.g., human 
anti-Rho [D] immune globulin) does not generally interfere with an immune response and is 
not a contraindication to postpartum vaccination. However, in this situation, serologic testing 
should be done 6-8 weeks after vaccination to assure that seroconversion has occurred.
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Rubella vaccine should not be given to pregnant women or to those likely to become preg­
nant within 3 months after receiving the vaccine. Through 1 983, CD C monitored prospective­
ly 21 4  susceptible pregnant women who had received rubella vaccine within 3 months before 
or after conception and carried their pregnancies to term (94 received Cendehill or HPV-77, 
11 9 received RA 27/3, and one received an unknown strain of vaccine). None of the infants 
had malformations compatible with C R S. The ACIP believes that the risk of vaccine- 
associated malformation is so small as to be negligible. Although a final decision must rest 
with the individual patient and her physician, the ACIP believes that rubella vaccination during 
pregnancy should not ordinarily be a reason to recommend interruption of pregnancy.
Because of the theoretical risk to the fetus, reasonable precautions should be taken before 
women of childbearing age are vaccinated. These precautions include 1) asking women if 
they are pregnant, 2) excluding those who say they are, and 3) explaining the theoretical risks 
of the vaccine to the others and counseling them not to become pregnant for 3 months after 
vaccination. If a pregnant woman is vaccinated or if a woman becomes pregnant within 3 
months after vaccination, she should be counseled on the theoretical risks to the fetus. In­
stances of vaccination of known  susceptible women who are pregnant or become pregnant 
within 3 months should be reported through state health departments to the Division of Im­
munization, CDC.
In general, rubella vaccine should not be given to persons who are immunocompromised 
as a result of immune deficiency diseases, leukemia, lymphoma, or generalized malignancy or 
are immunosuppressed as a result of therapy with corticosteroids, alkylating drugs, antime­
tabolites, or radiation. (See "Conditions That Compromise the Immune System," page 8S.)
Rubella vaccine is prepared in human diploid cell cultures and has not been reported to be 
associated with allergic reactions. The vaccine does contain trace amounts of neomycin to 
which patients may be allergic. Persons with a history of any sign or symptom of an 
anaphylactic reaction (i.e., hives, swelling of the mouth and throat, difficulty in breathing, hy­
potension, or shock) following receipt of neomycin should not receive rubella vaccine. Persons 
with reactions to neomycin that are not anaphylactic are not at increased risk and can be vac­
cinated. Rubella vaccine does not contain penicillin.
Sm a llp o x
In May 1 980, the World Health Organization (WHO) declared the world free of smallpox. A 
smallpox vaccination certificate is not required by any country as a condition of entry for inter­
national travelers. In May 1983, the distribution of smallpox vaccine for civilian use in the 
United States was discontinued.
* Vaccine indications
There is no evidence that smallpox vaccination has therapeutic value in the treatment of 
recurrent herpes simplex infection, warts, or any other disease. Smallpox vaccine should 
never be used therapeutically for these or any other conditions.
Except for persons working with orthopox viruses or involved in producing and testing 
smallpox vaccine, there are no indications for the use of smallpox vaccine in civilian popula­
tions. When indicated, smallpox vaccination should be given at least every 3 years. For advice 
on vaccine administration and contraindications, contact the International Health Program 
Office, C D C, Atlanta, Georgia 30333.
Yellow  F e v e r
Cases of yellow fever are reported only from Africa and South America. Two forms of 
yellow fever—urban and jungle —are distinguishable epidemiologically. Clinically and ecologi­
cally they are identical.
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Urban yellow fever is an epidemic viral disease transmitted from infected to susceptible 
persons by the Aedes aegypti mosquito. In areas where the A. aegypti mosquito has been 
eliminated or suppressed, urban yellow fever has disappeared. In West Africa, A. aegypti- 
transmitted epidemics involving town and village populations continue to occur at frequent 
intervals.
Jungle yellow fever is an enzootic viral disease transmitted among nonhuman hosts by a 
variety of mosquito vectors. It is currently observed only in forested areas of South America 
and forest-savannah zones of tropical Africa, but occasionally extends into Central America 
and the Caribbean. In tropical America 2 0 0 -4 0 0  cases are recognized annually, mainly among 
persons with occupational exposure to the vector in forested areas; the disease is, however, 
believed to be greatly underreported. In Africa, epidemics that are spread by forest mosquito 
vectors affect tens of thousands of persons every few years, but few cases are officially 
reported. The jungle yellow fever cycle may be active but unrecognized in forested areas of 
countries within the zone with endemic yellow fever (Figure 1).
• Yellow  fever vaccine
The yellow fever vaccine available in the United States is an attenuated, live-virus vaccine 
prepared from the 1 7D strain of virus grown in chick embryo. Immunity is induced by a single 
S C  injection of 0.5 ml of reconstituted vaccine and persists for more than 10 years.
Yellow fever vaccines must be approved by WHO and administered at an approved Yellow 
Fever Vaccination Center. Centers can be identified by contacting state and local health 
departments. Vaccinees should have an International Certificate of Vaccination filled out, 
dated, signed, and validated with the stamp of the center where the vaccine is given. Vaccine 
must be received 6 days to 10 years before travel in order for the certificate to be valid.
• Vaccine indications
Vaccination is recommended for persons traveling or living in areas where yellow fever in­
fection o ccurs—currently parts of Africa and South America. Information on known or proba­
bly infected areas are published annually in Health Inform ation fo r  International Travel. Coun­
FIG U R E 1. Yellow  fever endem ic zones
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tries currently reporting yellow fever are noted biweekly in Sum m ary o f Health Inform ation fo r 
International Travel. All state health departments and many county and city health depart­
ments receive these publications. It should be emphasized that the actual areas of yellow 
fever activity far exceed the zones officially reported to be infected. Vaccination is also 
recommended for laboratory personnel who might be exposed to virulent yellow fever virus.
Booster doses are needed at 1 O-year intervals.
Som e countries, especially in Africa, require evidence of vaccination from all entering trav­
elers. Other countries may waive the requirements for travelers coming from noninfected 
areas and staying less than 2 weeks. Some countries require a traveler, even if only in transit, 
to have a valid certificate if the traveler has visited any country thought to harbor yellow fever 
virus. Requirements of individual countries may change, and the most current information is 
published biweekly in Sum m ary o f Health Inform ation fo r International Travel and summarized 
annually in Health Inform ation fo r International Travel.
• Vaccine side effects and adverse reactions
Reactions to 17D yellow fever vaccine are generally mild. From 2% to 5% of vaccinees 
have mild headache, myalgia, low-grade fever, or other minor symptoms 5 -1 0  days after vac­
cination. Fewer than 0.2% curtail regular activities. Immediate hypersensitivity reactions, char­
acterized by rash, urticaria, and/or asthma, are extremely uncommon and occur principally in 
persons with a history of egg allergy. Although more than 34  million doses of vaccines have 
been distributed, only two cases of encephalitis temporally associated with vaccinations have 
been reported in the United States; in one fatal case, 1 7D virus was isolated from the brain.
• Vaccine precautions and contraindications
Yellow fever vaccine should not be given to persons who are immunocompromised as a 
result of immune deficiency diseases, leukemia, lymphoma, or generalized malignancy or are 
immunosuppressed as a result of therapy with corticosteroids, alkylating drugs, antimetabo­
lites, or radiation. (See "Conditions That Compromise the Immune System," page 8S.)
Although specific information is not available on adverse effects of yellow fever vaccine 
on the developing fetus, it is prudent on theoretical grounds to avoid vaccinating pregnant 
women and to advise that they postpone travel to areas where yellow fever occurs until after 
delivery. Pregnant women who must travel to areas where the risk of yellow fever is high 
should be vaccinated. It is believed that under these circumstances, the risk of yellow fever in­
fection far outweighs the small theoretical risk to mother and fetus from vaccination. Howev­
er, if international travel regulations constitute the only reason to vaccinate a pregnant woman 
or a patient hypersensitive to eggs, efforts should be made to obtain a letter of waiver from a 
physician clearly stating the contraindication to vaccination. Ideally, this letter should be writ­
ten on letterhead stationery and bear the stamp used by health departments and official im­
munization centers to validate the International Certificates of Vaccination. Such a letter of 
waiver has been acceptable to some governments. Under these conditions, it is also useful for 
the traveler to obtain specific, authoritative advice from the country or countries he or she 
plans to visit. Their embassies or consulates may be contacted, and a letter substantiating the 
waiver of requirements obtained.
Since live yellow fever vaccine is produced in chick embryos, persons with a history of any 
signs or symptoms of an anaphylactic reaction (i.e., hives, swelling of the mouth and throat, 
difficulty in breathing, hypotension, or shock) after eating eggs should not receive yellow 
fever vaccine. If vaccination of an individual with a questionable history of egg hypersensitivity 
is considered essential because of a high risk of exposure, an intradermal (ID) test dose may 
be administered under close medical supervision. Specific directions for skin testing are found 
in the package insert.
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Som e data have indicated that persons given yellow fever and cholera vaccines simultane­
ously or 1-3 weeks apart had lower-than-normal antibody responses to both vaccines. 
Unless there are time constraints, cholera and yellow fever vaccines should be administered 
at a minimal interval of 3 weeks. If the vaccines cannot be administered at least 3 weeks 
apart, then they should preferably be given simultaneously.
Yellow fever vaccine and commercially available IG may be given simultaneously.
Both Live-Virus and Inactivated-Virus Vaccines
P o lio m ye litis
The risk of poliomyelitis is very small in the United States; however, epidemics could 
occur if the high immunity level of the general population is not maintained by immunizing 
children routinely or if wild poliovirus is introduced into susceptible populations in communi­
ties with low immunization levels. In the United States inapparent infection with wild poliovirus 
strains no longer contributes significantly to establishing or maintaining immunity. Most 
adults are already immune.
• Poliovirus vaccines
Two types of poliovirus vaccines are currently licensed in the United States: OPV and IPV. 
A primary vaccination series with either vaccine produces immunity to all three types of polio­
virus in more than 95% of recipients. The primary series of OPV consists of three doses: two 
doses given 6 -8  weeks apart and a third dose given at least 6 weeks and customarily 6 -12  
months after the second. The primary series for IPV consists of four doses: three doses each 
given 4 -8  weeks apart and a fourth dose given 6 -1 2  months after the third. In general, it is 
not necessary to give a primary vaccine series to adults living in the United States who have 
not had a primary series as children. However, for adults who have not had a primary series 
and who are at greater risk than the general population of exposure to wild polioviruses be­
cause of foreign travel or health occupation, IPV is preferred since the risk of OPV-associated 
paralysis is slightly higher in adults than in children.
Poliovirus vaccine is not routinely recommended for persons older than high school age 
(18-19 years old).
• Vaccine indications
Travelers to areas where wild poliovirus is epidemic or endemic should have completed a 
primary series of poliovirus vaccine. For previously unimmunized persons, IPV is indicated. 
However, if less than 4 weeks are available before protection is needed, a single dose of OPV 
is recommended. Travelers who have previously received less than a full primary course of 
OPV or IPV should be given the remaining required doses of either vaccine, regardless of the 
interval since the last dose and the type of vaccine previously received. Travelers to develop­
ing countries who have previously completed a primary series of OPV should receive a single 
dose of OPV. Additional booster doses of O PV are probably not necessary. Those who have 
previously received a primary series of IPV should receive a dose of either OPV or IPV. If IPV is 
used exclusively, an additional dose may be given every 5 years if exposure continues or 
recurs, although the need for these boosters has not been established.
Health-care personnel in close contact with patients who may be excreting wild poliovi­
ruses, and laboratory personnel handling specimens that may contain wild polioviruses, 
should have completed a primary series of poliovirus vaccine. IPV is indicated because of the 
slightly increased risk to adults of vaccine-associated paralysis after OPV administration; 
also, virus may be shed after receipt of OPV vaccine and inadvertently expose susceptible im­
munocompromised contacts to live vaccine virus.
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• Vaccine adverse reactions
Inactivated poliovirus vaccine. No serious side effects of currently available IPV have been 
documented. Since IPV contains trace amounts of streptomycin and neomycin, hypersensitivi­
ty reactions are possible in individuals sensitive to these antibiotics. Persons with signs and 
symptoms of an anaphylactic reaction (i.e., hives, swelling of mouth and throat, difficulty in 
breathing, hypotension, or shock) following receipt of streptomycin or neomycin should not 
receive IPV. Persons with reactions that are not anaphylactic are not at increased risk and can 
be vaccinated.
Oral poliovirus vaccine. In rare instances, administration of OPV has been associated with 
paralysis in healthy recipients and their contacts. Although the risk of vaccine-associated 
paralytic poliomyelitis is extremely small for immunologically normal vaccinees (approximate­
ly one case per 9 million doses distributed) and their susceptible, immunologically normal 
household contacts (approximately one case per 7 million doses distributed), vaccinees 
should be informed of this risk.
• Vaccine precautions and contraindications
Inactivated poliovirus vaccine. There is no convincing evidence of adverse effects of IPV 
for the pregnant woman or developing fetus; regardless, it is prudent on theoretical grounds 
to avoid vaccinating pregnant women. However, if immediate protection against poliomyelitis 
is needed. OPV, not IPV, is recommended.
Oral poliovirus vaccine. Unlike other live-virus vaccines, which are administered parenteral­
ly, OPV is administered orally. IG and other antibody-containing blood products do not 
appear to interfere with the immune response to OPV.
OPV should not be given to persons who are or may be immunocompromised as a result 
of immune deficiency diseases, leukemia, lymphoma, or generalized malignancy or immuno- 
suppressed as a result of therapy with corticosteroids, alkylating drugs, antimetabolites, or ra­
diation. (See "Conditions That Compromise the Immune System," page 8S.) If immunization 
against poliomyelitis is indicated in such persons, IPV should be used, and some protection 
may result.
OPV should not be used for immunizing household contacts of patients immunocompro­
mised as a result of immune deficiency disease, leukemia, lymphoma, or generalized 
malignancy or immunosuppressed as a result of therapy with corticosteroids, alkylating 
drugs, antimetabolites, or radiation. If protection is indicated, IPV should be used for immuniz­
ing household contacts of such patients. OPV should not be given to anyone in a family with a 
known family history of immunodeficiency until the immune status of all family members is 
documented.
When children in the household are given OPV, adults who are not adequately immunized 
against poliomyelitis are at a very small risk of contracting OPV-associated paralytic polio­
myelitis. Because of the overriding importance of ensuring prompt and complete immunization 
of the child and the extreme rarity of OPV-associated disease in contacts of vaccinees, the 
ACIP recommends the administration of O PV to a child regardless of the poliovirus-vaccine 
status of adult household contacts. This is the usual practice in the United States. The re­
sponsible adult should be informed of the small risk involved and of precautions to be taken, 
such as hand washing after changing a diaper. An acceptable alternative, if there is strong 
assurance that ultimate, full immunization of the child will not be jeopardized or unduly 
delayed, is to immunize adults with IPV or OPV, as appropriate to their immunity status, 
before giving OPV to the child.
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Inactivated-Virus Vaccines 
H e p a titis  B  Virus In fectio n
The estimated lifetime risk of acquiring HBV infection in the United States is approximately 
5% for the population as a whole but may approach 100% for the highest risk groups. Annual­
ly, an estimated 100 ,000  symptomatic cases of hepatitis B disease occur in the United 
States, leading to approximately 10,000 hospitalizations and 190 fulminant cases. Three- 
fourths of persons with fulminant disease die.
In 1982, 88% of hepatitis B cases for which patient age was known occurred in persons 
20 years of age or older. Between 6% and 10% of adults with HBV infection become carriers. 
The United States currently has 4 0 0 ,0 0 0 -8 0 0 ,0 0 0  carriers. Chronic active hepatitis occurs in 
25% of carriers. Each year in the United States, approximately 4 ,0 0 0  persons die of HBV- 
related cirrhosis, and 800, of HBV-related liver cancer.
• Hepatitis B vaccine
A series of three 1 -ml IM doses of HB vaccine, each containing 20  /ug/ml of HBsAg protein, 
provides protective antibody in over 90% of healthy adult recipients and is 80% -95%  effective 
in preventing infection for at least 2 years. The first two doses should be given 1 month apart, 
and the third dose, 5 months after the second. The duration of vaccine-induced protection 
and the need for booster doses are not yet known. For susceptible hemodialysis patients, 
three 2-m l doses given at the above intervals are recommended. Because the prevalence of 
HBV varies widely among various population groups, serologic screening to detect susceptible 
individuals before vaccination may or may not be cost effective. Cost effectiveness depends 
on the known or perceived risk of infection, the cost of screening, and the cost of HB vaccine.
• Vaccine indications
Immunization is recommended for adults at increased risk of occupational, social, family, 
environmental, or illness-related exposure to HBV. These include homosexual males, users of 
illicit injectable drugs, household and sexual contacts of HBV carriers, workers in health- 
related occupations requiring frequent exposure to blood, residents and staff of institutions 
for the mentally retarded, hemodialysis patients, recipients of factor VIII or IX concentrates, 
and morticians and their assistants. Inmates in some long-term correctional facilities may also 
be candidates for vaccination.
Vaccination should also be considered for persons who plan to reside for more than 6 
months in areas with high levels of endemic HBV and who will have close contact with the 
local population and for travelers intending a short stay who are likely to have contact with 
blood from or sexual contact with residents of areas with high levels of endemic disease (par­
ticularly areas of eastern Asia and Sub-Saharan Africa). Such persons should allow 6 months 
before travel in order to complete the HB vaccine primary series.
HB vaccine is intended primarily for preexposure prophylaxis. However, it has recently 
been recommended for postexposure use in certain situations, particularly for persons who 
belong to a high-risk group for whom preexposure administration of vaccine is recommended 
( 3 ). HB vaccine in combination with HBIG provides sustained protective levels of antibody and 
obviates the need for a second dose of HBIG in such exposures. Therefore, a normal series of 
HB vaccine, combined with a single dose (0.06 ml/kg or 5 ml for adults) of HBIG given at a dif­
ferent site, is recommended for postexposure prophylaxis of health workers following acci­
dental percutaneous or mucous-membrane exposure to blood containing HBsAg, and of su s­
ceptible homosexual men following sexual exposure to an HBsAg-positive man. HBIG alone 
(in the same dose) is recommended for postexposure prophylaxis of persons with heterosexu­
al exposures.
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• Vaccine side effects and adverse reactions
In vaccine trials, soreness at the site of injection was the only side effect that occurred 
more frequently for vaccinees than for controls. Since its licensure in 1981 through August 
1 983, HB vaccine is estimated to have been administered to over 3 5 0 ,0 0 0  individuals in the 
United States. As of May 1 984, adverse events following immunization had been reported for 
8 90  vaccinees. The reported adverse events represent temporal associations with vaccination 
and are not necessarily caused by the vaccine. Forty-eight persons had serious events such as 
transverse myelitis, grand mal seizures, aseptic meningitis, erythema multiforme, or Guillain- 
Barre syndrome (GBS).
• Vaccine precautions and contraindications
Pregnancy should not be considered a contraindication to vaccinating women who are oth­
erwise candidates for receiving HB vaccine. While data are not available on the safety of the 
vaccine for the developing fetus, HB vaccine contains only noninfectious HBsAg particles and 
should pose no risk to the fetus. In contrast, HBV infection in a pregnant woman may result in 
a severe disease for the mother and chronic infection for the newborn.
Since HB vaccine is made from human plasma, the possibility that it may contain an etio- 
logic agent of acquired immunodeficiency syndrome (AIDS) has been raised. The purification 
and inactivation process used in preparing HB vaccine inactivates representatives of all known 
groups of viruses. There are no microbiologic, epidemiologic, or empiric data to suggest that 
the HB vaccine carries any etiologic risk for AIDS.
In fluenza
Influenza viruses have continually demonstrated the ability to cause major epidemics of re­
spiratory disease. High attack rates of acute illness and the frequent occurrence of lower- 
respiratory-tract complications usually result in dramatic rises in visits to physicians' offices 
and hospital emergency rooms. Furthermore, influenza frequently infects individuals who, be­
cause of their age or underlying health status, are poorly able to cope with the disease and 
often require medical attention, including hospitalization. Such persons are considered to be 
medically at "high risk" in epidemics. In one recent study, for example, rates of hospitalization 
for adults with "high-risk" medical conditions increased during major epidemics by about 
two- to fivefold in different age groups, reaching a maximum rate of about 8 00  per 100,000 
population.
Influenza epidemics cause excess mortality, which is attributable not only to influenza 
pneumonia, but also to cardiopulmonary disease. Fifteen times in the years 1 9 5 7 -1 9 8 2 , 
epidemics have been associated with 10,000 or more excess deaths; in 1983, excess mor­
tality again exceeded the epidemic threshold.
The greatest impact of influenza is normally seen when new strains appear against which 
most of the population lacks immunity. In these circumstances (e.g., 1957 and 1968), 
pandemics occur. During pandemics, a quarter or more of the United States population have 
been affected over a period of 2-3 months.
Because the proportion of elderly persons in the United States is increasing, and because 
age and its associated chronic diseases are risk factors for severe influenza illness, the toll of 
influenza may also increase unless control measures are used more vigorously than in the past.
• Influenza vaccine
Influenza A viruses are classified into subtypes on the basis of two antigens: hemagglutinin 
(H) and neuraminidase (N). Three subtypes of hemagglutinin (H1, H2, H3) and two subtypes of 
neuraminidases (N1, N2) are recognized among influenza A viruses that have caused wide­
spread human disease. Immunity to these antigens, especially hemagglutinin, reduces the
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likelihood of infection and the severity of disease if a person does become infected. However, 
there may be sufficient antigenic variation (antigenic drift) within the same subtype overtime, 
so that infection or vaccination with one strain may not induce immunity to distantly related 
strains of the same subtype. Although influenza B viruses have shown much more antigenic 
stability than influenza A viruses, antigenic variation does occur. As a consequence, the an­
tigenic characteristics of current strains provide the basis for selecting virus strains to be 
included in the vaccine for a given year.
Potency of present vaccines is such that nearly all vaccinated young adults develop 
hemagglutination-inhibition antibody titers that are likely to protect them against infection by 
strains like those in the vaccine, and often by related variants that emerge. The elderly, the 
very young, and patients with certain chronic diseases may develop lower postvaccination an­
tibody titers than do young adults. Under these circumstances, influenza vaccine may be 
more effective in preventing lower-respiratory-tract involvement, or other complications of in­
fluenza, than in preventing upper-respiratory-tract involvement. Influenza vaccine will not pre­
vent primary illnesses caused by other respiratory pathogens.
• Vaccine indications
Use of inactivated influenza vaccine is the single most important measure in the prevention 
and/or attenuation of influenza infection. Since 1 963, annual vaccination against influenza 
has been recommended for individuals at high risk of lower-respiratory-tract complications 
and death following influenza infection (i.e., the elderly and persons with chronic disorders of 
the cardiovascular, pulmonary, and/or renal system s; metabolic diseases; severe anemia; 
and/or compromised immune function). These groups have been identified primarily by 
review of death certificate data, supported by hospital-based or population-based studies. 
Within each broadly defined "high-risk" category, however, some persons are more likely 
than others to suffer severe complications from influenza infection.
Among nursing-home residents, chronic diseases and other debilitating conditions are 
common, and spread of influenza can often be explosive, with attack rates as high as 60% 
and case-fatality ratios up to 30% or higher. In addition, recent retrospective studies of nonin­
stitutionalized patients suggest that chronic underlying diseases, particularly those that affect 
the cardiovascular and pulmonary systems, may contribute more to the severity of illness 
than does age alone.
Medical personnel may transmit influenza infections to their high-risk patients while they 
are themselves incubating an infection, undergoing a subclinical infection, or working while 
they have mild symptoms. Nosocomial outbreaks of influenza are reported. The potential for 
introducing influenza to a high-risk group such as patients with severely compromised cardio­
pulmonary or immune system s or infants in neonatal intensive care units should be reduced 
by targeted vaccination programs of medical personnel.
Based on these observations, the previous, broadly defined "high-risk" adult groups have 
been further assigned priority for receiving vaccine in order that special efforts can be directed 
at providing vaccine to those who may derive the greatest benefit.
1. Adults at high risk of severe influenza illness who most warrant active, targeted vacci­
nation efforts:
(a) Adults with chronic disorders of the cardiovascular or pulmonary system s that are 
severe enough to require regular medical follow-up or to have caused hospitalization 
during the preceding year.
(b) Residents of nursing homes and other chronic-care facilities (e.g., institutions hous­
ing patients of any age with chronic medical conditions). Achievement of high vacci­
nation rates (e.g., 80%) may induce herd immunity in such populations and thereby
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lower the frequency of outbreaks, as well as reducing the frequency of severe illness 
when outbreaks do occur.
2. Physicians, nurses, and other personnel who have extensive contact with high-risk pa­
tients (e.g., primary-care and certain specialty clinicians and staff of intensive-care 
units). These persons should receive influenza vaccination annually to reduce the possi­
bility for nosocomial spread of influenza to high-risk patients.
3. Other adults who are at moderately increased risk of serious illness compared with the 
general population. Special programs to make vaccine readily available to these groups 
should also be given high priority:
(a) Healthy individuals over 65 years of age.
(b) Adults with a chronic metabolic disease (including diabetes mellitus), renal dysfunc­
tion (including those in chronic dialysis), anemia, immunosuppression, or asthma 
that is severe enough to require regular medical follow-up or to have caused hospi­
talization during the preceding year.
In addition, influenza vaccine may be offered to persons who provide essential community 
service or to any adult who wishes to reduce the likelihood of an influenza infection.
Effective programs for giving influenza vaccine are needed in nursing homes and other 
chronic-care facilities, in physicians' offices, and in hospital settings. Residents of nursing 
homes and chronic-care facilities should receive routine annual vaccination. Other adult high- 
priority groups should receive influenza vaccine at the time of regular medical follow-ups in 
the fall, or should be notified to come in specifically to receive the vaccine. Patients with high­
risk conditions who are hospitalized during the fall should be considered for influenza vaccine 
before discharge from the hospital.
There is considerable overlap in the target groups for influenza vaccination and those for 
pneumococcal polysaccharide vaccine. Pneumococcal polysacchraride vaccine and influenza 
vaccine can be given at the same time at different sites without an increase in side effects; 
however, it should be emphasized that whereas influenza vaccine is given annually, pneumo­
coccal polysaccharide vaccine should be given only once to adults. Detailed immunization 
records should be provided to each patient to help ensure that additional doses of pneumo­
coccal polysaccharide vaccine are not given.
Amantadine hydrochloride, an antiviral drug, can prevent influenza A or be used therapeuti­
cally to reduce symptoms of influenza A infections. It is not a substitute for vaccine. Specific 
circumstances in which amantadine prophylaxis is recommended are described in the ACIP 
recommendations on prevention and control of influenza.
* Vaccine side effects and adverse reactions
Vaccines used in recent years have generally been associated with only a few reactions. 
Fewer than one-third of vaccinees have been reported to develop local redness or induration 
for 1 or 2 days at the site of injection.
System ic reactions have been of two types. First, malaise, myalgia, and other systemic 
symptoms of toxicity, although infrequent, most often affect those who have had no experi­
ence with the influenza virus antigens contained in the vaccine. These reactions, which begin 
6 -1 2  hours after vaccination and persist for 1-2 days, are usually attributed to the influenza 
antigens (even though the virus is inactivated) and constitute most of the system ic side ef­
fects of influenza vaccination.
Second, immediate, presumably allergic, responses such as flare and wheal or various 
respiratory-tract symptoms of hypersensitivity occur extremely rarely after influenza vaccina­
tion. These sym ptom s probably result from sensitivity to some vaccine component —most 
likely residual egg protein. Although current influenza vaccines contain only a small quantity 
of egg protein, on rare occasions vaccine can induce hypersensitivity reactions. Unlike the
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1 976 swine influenza vaccine, vaccines used subsequently have not been associated with an 
increased frequency of GBS.
• Vaccine precautions and contraindications
Pregnancy has not been demonstrated to be a risk factor for severe influenza infection 
except in the largest pandemics of 1 9 1 8 -1 9 1 9  and 1 957-1 958. Influenza vaccine is consid­
ered to be generally safe for pregnant women. Nonetheless, when vaccine is to be given 
during pregnancy, waiting until the second or third trimester is a reasonable precaution to 
minimize any concern over theoretical teratogenicity.
Persons with a history of any signs or symptoms of an anaphylactic reaction (i.e., hives, 
swelling of the mouth and throat, difficulty in breathing, hypotension, or shock) after eating 
eggs should not be given inactivated influenza vaccine.
Persons with acute febrile illnesses normally should not be vaccinated until their temporary 
sym ptom s have abated.
R a b ies
Although rabies rarely affects humans in the United States, thousands of persons receive 
rabies vaccine every year, principally for postexposure prophylaxis. The likelihood of human 
exposure to rabies from domestic animals has decreased greatly in recent years. In every year 
since 1 976, more than 85% of all reported cases of animal rabies have been among wild ani­
mals, the most important source of possible infection for humans in the United States. How­
ever, for persons traveling overseas to developing countries with endemic rabies, the dog re­
mains the animal most likely to transmit rabies.
• Rabies vaccine
Both whole-virion and subvirion human diploid cell rabies vaccines (HDCV) are available. 
For preexposure rabies prophylaxis a three-dose series of HDCV of either type given as 1 -ml 
doses IM on days 0, 7, and 28 provides adequate antibody levels in virtually all recipients (10) .  
The CD C currently accepts a titer of 5 by the rapid fluorescent-focus inhibition test as 
adequate.
The whole-virion HDCV produced by the Merieux Institute has been used for preexposure 
immunization in a regimen of three 0 .1 -ml doses given intradermally (ID) in the lateral aspect 
of the upper arm in the deltoid area, one dose on each of days 0, 7, and 28. Experience gained 
with over 2 ,0 0 0  persons vaccinated in the United States by the ID route has shown that anti­
body is produced in all recipients, although the mean response is somewhat lower and may 
be of shorter duration than with comparable IM immunization. Except for persons suspected 
of being immunosuppressed, postvaccination serology is not necessary following IM or ID im­
munization in the United States. Antibody response in some groups vaccinated ID outside the 
United States has been found to be inadequate for reasons not yet determined (11) .  Prelimi­
nary data suggest that concurrent administration of malaria chemoprophylaxis may be a 
factor in the lowered immunologic response of persons vaccinated overseas. It should be 
noted that Merieux Institute, the manufacturer, has not yet met the packaging and labeling re­
quirements necessary to obtain approval by the FDA for the ID route of administration. The 
1 -ml vial presently available is intended for IM use and contains no preservatives. To minimize 
the risk of contamination and loss of vaccine potency, the reconstituted vaccine must be used 
immediately. Data on ID immunization are not available for Wyeth Laboratories vaccine.
Proper postexposure rabies prophylaxis is determined by whether or not the person has 
had previous preexposure or postexposure prophylaxis. 1) Persons who (a) have previously 
received postexposure prophylaxis with HDCV, (b) have received a three-dose IM preexposure 
regimen of HDCV, (c) have received a three-dose ID preexposure regimen of HDCV in the
United States, or (d) have a previously documented adequate rabies titer should receive two
1-ml IM doses of H D C V —one dose on each of days 0 and 3. HRIG is not recommended in 
these circumstances. 2) Persons not meeting the above criteria should be treated with a 
single, 20-international units (IU)/kg dose of HRIG and five 1-ml doses IM of HDCV —one on 
each of days 0, 3, 7, 14, and 28. HRIG should be administered at the beginning of HDCV post­
exposure prophylaxis but can be given up to the eighth day after the first dose of HDCV was 
given. The HRIG dose should be divided; up to half should be infiltrated into the area of the 
wound, if possible, and the rest administered IM, but not in the same site as HDCV. Only IM ad­
ministration of HDCV is indicated for postexposure prophylaxis.
• Vaccine indications
Preexposure immunization should be considered for high-risk groups: animal handlers, cer­
tain laboratory workers and field personnel, and persons planning to be in countries or areas 
of countries for more than 1 month where rabies is a constant threat. Persons whose voca­
tions or avocations bring them into contact with potentially rabid animals should also be con­
sidered for preexposure immunization. Persons with continuing risk of exposure should re­
ceive a booster dose every 2 years or have their serum tested for rabies antibody every 2 
years and, if the titer is inadequate, be given a booster dose. If there is substantial risk of expo­
sure to rabies, preexposure rabies prophylaxis may be indicated during pregnancy.
The decision to provide specific postexposure antirabies treatment should include the fol­
lowing considerations:
1 Type of exposure—rabies is transmitted primarily by the bite of infected animals. It may 
also be transmitted by introducing the virus into open cuts or wounds in skin or via 
mucous membranes by saliva or other potentially infectious material from a rabid 
animal and, rarely, by aerosol exposure.
2. Species of biting animal —carnivorous wild animals (especially skunks, raccoons, and 
foxes) and bats are most commonly infected with rabies in the United States. Elsewhere 
in the world, dogs, cats, carnivorous wildlife, and bats are the major vectors. The likeli­
hood that domestic cats or dogs in the United States will be infected varies from region 
to region. Rodents are rarely infected. Consultations with the state or local health 
department may be helpful.
3. Circum stances of biting incident —an unprovoked attack is more indicative of a rabid 
animal than a provoked attack.
• Vaccine side effects and adverse reactions
Following postexposure prophylaxis, local reactions, such as pain, erythema, and swelling 
or itching at the injection site, are very common, and mild systemic reactions, such as head­
ache, nausea, abdominal pain, muscle aches, and dizziness, are reported by about 20% of reci­
pients. System ic allergic reactions ranging from hives to anaphylaxis occur in an estimated 11 
per 10,000 vaccinees. Mild immune-complex-like hypersensitivity reactions consisting of 
hives, itching, and angio-edema have occurred 2-21 days after booster doses of HDCV and 
are the most frequently reported allergic reactions ( 12 ). Four cases of transient neuroparalytic 
illness have been temporally associated with HDCV administration: two following administra­
tion of whole-virion vaccine and two following administration of subvirion vaccine (13) .  No 
permanent sequelae or deaths have been associated with administration of HDCV.
• Vaccine precautions and contraindications
Corticosteroids and other immunosuppressive agents can interfere with the development 
of active immunity and should not be administered during preexposure therapy. When rabies 
postexposure prophylaxis is administered to persons known or suspected of being immuno- 
suppressed, or to those who are receiving steroids or immunosuppressive therapy, it is espe­
cially important that serum be tested to ensure an adequate rabies antibody response.
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If a person experiences an anaphylactic reaction (i.e., hives, swelling of the mouth and 
throat, difficulty in breathing, hypotension, or shock) after receiving HDCV, no further preex­
posure doses of HDCV should be given. By contrast, if a person needing postexposure therapy 
has had a previous anaphylactic reaction to HDCV or has such a reaction during the postexpo­
sure course, HDCV therapy should continue; however, the person should receive the required 
doses in an appropriate medical setting.
Inactivated-Bacteria Vaccines
Cholera
Cholera continues to be a health risk in Africa and Asia. Countries currently reporting chol­
era are listed in the biweekly publication Sum m ary o f Health Inform ation fo r International 
Travel. All state health departments and many county and city health departments receive 
this publication. Persons who follow the usual tourist itinerary and who use tourist accom m o­
dations in countries affected by cholera are at virtually no risk of infection. The traveler's best 
protection against cholera is avoiding food and water that might be contaminated.
• Cholera vaccine
The vaccine may be administered as a 0.5-m l dose S C  or IM or as a 0.2-m l dose ID. A l­
though a single dose of vaccine is sufficient for entry into most countries, some countries 
may require evidence of a complete primary series of two doses given 1 week to 1 month or 
more apart, or a booster dose within 6 months before arrival.
The currently available cholera vaccine has been shown in field trials to be only about 50% 
effective in preventing clinical illness for a period of 3 -6  months. The vaccine does not prevent 
transmission of infection. The risk of cholera to most U.S. travelers is so low that it is doubtful 
that vaccination is of benefit. WHO no longer recommends cholera vaccination for travel to or 
from cholera-infected areas. However, some countries affected or threatened by cholera re­
quire evidence of cholera vaccination as a condition of entry. Current information on cholera- 
vaccination requirements of individual countries is published annually in Health Inform ation  
fo r International. Travel. All state health departments and many county and city health depart­
ments receive this publication. Travelers to countries with cholera-vaccination requirements 
should have an International Certificate of Vaccination filled in, dated, signed, and validated 
showing receipt of the vaccine 6 days to 6 months before entry into the country. Most city, 
county, and state health departments can validate certificates. Failure to secure validation 
may cause travelers to be revaccinated or quarantined
• Vaccine indications
Cholera vaccine is indicated only for travelers to countries requiring evidence of cholera 
vaccination for entry. Boosters may be given every 6 months if required by a country.
• Vaccine side effects and adverse reactions
Vaccination often results in 1 -2 days of pain, erythema, and induration at the site of injec­
tion. The local reaction may be accompanied by fever, malaise, and headache. Serious reac­
tions, including neurologic reactions, following cholera vaccination are extremely rare.
• Vaccine precautions and contraindications
No specific information is available on the safety of cholera vaccine during pregnancy. Be­
cause cholera disease during pregnancy is a serious illness, whether to use cholera vaccine 
should be determined in individual circumstances based on the actual risk of disease and the 
probable benefits of the vaccine.
The only contraindication to cholera vaccine is a history of a severe reaction following a 
previous dose. Most governments will permit an unvaccinated traveler to enter the country if
Vol. 33/No. 1S MMWR 2 9S
he or she carries a physician's statement of medical contraindication. However, some coun­
tries may quarantine such unvaccinated persons or place them under surveillance if they 
come from areas with cholera.
Som e data have indicated that persons given yellow fever and cholera vaccines simultane­
ously or 1-3 weeks apart had lower-than-normal antibody responses to both vaccines. 
Unless there are time constraints, cholera and yellow fever vaccines should be administered 
at a minimal interval of 3 weeks. If the vaccines cannot be administered at least 3 weeks 
apart, then they should preferably be given simultaneously.
M e n in g o co cca l D ise a se
Meningococcal disease is endemic throughout the world but may also occur in epidemics. 
Among U.S. civilians, meningococcal disease occurs primarily as single, isolated cases or, in­
frequently, in small, localized clusters. A third of all cases of meningococcal disease occur in 
patients 20 years old or older. Serogroup B strains cause the majority of U.S. cases, with 
serogroups C and W1 35 strains accounting for most of the remainder.
• M eningococcal polysaccharide vaccine
Two meningococcal polysaccharide vaccines, bivalent A -C  and quadrivalent A, C, Y, and 
W1 35 vaccines, are available for use in the United States. Each is given as a single dose, and 
each induces specific serogroup immunity. The duration of immunity conferred by the vac­
cines is not known.
• Vaccine indications
Vaccine may be of benefit as an adjunct to antibiotic chemoprophylaxis for household and 
other close contacts of persons with meningococcal disease caused by serogroups A, C, Y, 
and W 135 and for travelers to areas with epidemic meningococcal disease. The need for 
booster doses has not been established.
Routine vaccination of U.S. civilians with meningococcal polysaccharide vaccine is not 
recommended because of the lack of availability of a group B vaccine and the low risk of in­
fection in the United States.
• Vaccine side effects and adverse reactions
Adverse reactions to meningococcal polysaccharide vaccines are infrequent and mild, con­
sisting principally of localized erythema lasting 1 -2 days.
• Vaccine precautions and contraindications
The safety of meningococcal polysaccharide vaccines for pregnant women has not been 
established. On theoretical grounds, it is prudent not to use them unless there is a substantial 
risk of infection.
Plague
Plague is a natural infection of rodents and their fleas. In the United States a few human 
cases occur yearly in humans exposed in the Western states to infected animals, primarily ro­
dents, and their fleas. Other countries currently reporting plague infections are noted in the 
biweekly publication Sum m ary o f Health Inform ation fo r International Travel. All state health 
departments and many county and city health departments receive this publication. A number 
of countries in Africa, Asia, and South America continue to report sporadic, epidemic, and epi­
zootic infection. In most of these countries, the risk of exposure exists primarily in rural or 
semirural areas.
• Plague vaccine
A primary series of plague vaccine consists of three IM doses. The first dose, 1 ml, is fol­
lowed in 4 weeks by a second dose of 0.2 ml. The third dose, also 0.2 ml, is administered 5
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months after the second. The effectiveness of a primary series of plague vaccine has never 
been measured precisely. Field experience indicates that vaccination with plague vaccine 
reduces the incidence and severity of disease resulting from the bite of infected fleas. The 
degree of protection offered against primary pneumonic infection is unknown. Since plague 
vaccination may only ameliorate illness, prophylactic antibiotics may be indicated whenever a 
person, vaccinated or not, has a definite exposure.
• Vaccine indications
Vaccination is indicated for certain vocational groups. These include all laboratory and 
field personnel working with Yersinia pestis  organisms that may be resistant to antimicro­
bials, persons engaged in aerosol experiments with Y. pestis, and field personnel engaged in 
operations in areas with enzootic or epidemic plague where preventing exposure to rodents 
and fleas is impossible. Plague vaccination should be considered for laboratory personnel 
regularly working with Y. pestis  or plague-infected rodents and for persons whose vocation 
regularly exposes them to wild rodents or rabbits in areas with enzootic plague.
Vaccine may also be considered for travelers to areas known to have endemic plague in 
countries reporting plague, particularly if travel will not be limited to urban areas with tourist­
hotel accommodations.
For persons with continuing exposure, three booster doses, each 0.1-0.2  ml, should be 
given at approximately 6-month intervals. Thereafter, booster doses at 1- to 2-year intervals 
should provide good protection.
• Vaccine side effects and adverse reactions
For about 10% of recipients, primary vaccination may result in general malaise, headache, 
fever, mild lymphadenopathy, and/or erythema and induration at the injection site. These 
reactions occur more commonly with repeated injections. Sterile abscesses occur rarely. Sen­
sitivity reactions manifested by urticarial and asthmatic phenomena have occasionally been 
reported.
• Vaccine precautions and contraindications
Neither the safety nor efficacy of vaccination with plague vaccine during pregnancy has 
been determined; therefore, it should not be used unless there is a substantial risk of infection.
Plague vaccine should not be administered to anyone with a known hypersensitivity to any 
of its constituents (beef protein, soy, casein, and phenol). Patients who have had severe local 
or systemic reactions to plague vaccine should not be revaccinated.
P n e u m o co cca l D ise a se
Precise data on the occurrence of serious pneumococcal disease in the United States are 
not available: however, the annual incidence rate of pneumococcal pneumonia is estimated to 
be 68 cases to 2 60  cases per 100,000 population, and of bacteremia, 7 -25 /10 0,000 . The 
incidence of pneumococcal pneumonia, which causes a substantial number of deaths annual­
ly, increases in those over 40  years old, and show s a twofold increase in those over 60 years 
of age. Mortality from pneumococcal disease is highest among patients who have bacteremia 
or meningitis, patients with underlying medical conditions, and older persons.
Patients with certain underlying conditions are clearly at increased risk both of contracting 
pneumococcal infection and of experiencing more severe pneumococcal illness. These condi­
tions include sickle cell anemia, multiple myeloma, cirrhosis, alcoholism, nephrotic syndrome, 
renal failure, splenic dysfunction, anatomic asplenia, and organ transplant. Persons suffering 
from diabetes mellitus, chronic pulmonary disease, cardiovascular disease, or conditions asso­
ciated with immunosuppression may be at increased risk of contracting pneumococcal infec­
tion or of having more severe illness.
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* Pneum ococcal polysaccharide vaccine
The pneumococcal polysaccharide vaccine currently available contains purified capsular 
materials of the 23 types of Streptococcus pneumoniae  responsible for 87% of recent bac- 
teremic pneumococcal disease in the United States. Most healthy adults show a twofold rise 
in type-specific antibody 2-3 weeks after administration of a single dose of vaccine. The titer 
of antibody that is protective against each serotype has not been determined.
The duration of vaccine-induced immunity is unknown. Studies of persistence of vaccine- 
induced antibody show elevated titers 3-5  years after immunization. Booster doses are not 
recommended because of increased adverse reactions to subsequent doses.
Patients who have received the earlier pneumococcal polysaccharide vaccine containing 
capsular material from only 14 types of S. pneumoniae  should not receive a dose of the 23- 
valent pneumococcal polysaccharide vaccine since the modest increase in coverage does not 
warrant the increased risk of adverse reactions.
* Vaccine indications
Newly available data regarding vaccine efficacy support the broader use of pneumococcal 
polysaccharide vaccine in the United States. Vaccination is particularly recommended for the 
following:
1) Adults with chronic illnesses, especially those with cardiovascular disease and chronic 
pulmonary disease, who sustain increased morbidity with respiratory infections.
2) Adults with chronic illnesses specifically associated with an increased risk of pneumo­
coccal disease or its complications. These include splenic dysfunction or anatomic 
asplenia, Hodgkins' disease, multiple myeloma, cirrhosis, alcoholism, renal failure 
(including those on chronic dialysis), cerebrospinal-fluid leaks, and conditions associat­
ed with immunosuppression.
3) Older adults, especially those age 65 and over, who are healthy.
Programs for vaccine delivery in the recommended high-risk groups need to be developed 
further. Specifically, more effective programs are needed for giving vaccine in physicians' of­
fices, in hospitals, and in nursing homes and other chronic-care facilities.
Since two-thirds of persons with serious pneumococcal disease have been hospitalized 
within 5 years before the pneumococcal illness ( 14),  vaccine should be given to hospitalized 
patients in the high-risk groups before discharge, in order to prevent future admissions for 
pneumococcal disease. In addition, persons with chronic conditions who visit physicians fre­
quently are probably at higher risk of pneumococcal infection than those who require infre­
quent visits. Office-based programs to identify and immunize patients requiring frequent 
medical care should help prevent pneumococcal illness. Furthermore, pneumococcal polysac­
charide vaccine and influenza vaccine can be given at different sites at the same time without 
an increase in side effects (75).
Medicare has partially reimbursed the cost of pneumococcal polysaccharide vaccination 
since 1981. It has been determined that hospitals may be reimbursed for pneumococcal im­
munization of Medicare recipients independent of reimbursement based on system s of pros­
pective payments.
* Vaccine side effects and adverse reactions
About half of the persons given pneumococcal polysaccharide vaccine experience mild 
side effects such as erythema and pain at the site of injection. Fever and myalgias have been 
reported by fewer than 1% of those given pneumococcal polysaccharide vaccine (7 6). 
Severe adverse effects such as anaphylactic reactions have rarely been reported —about five 
cases per million doses administered.
Arthus reactions and systemic reactions have been common among adults given second
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doses (1 7). They are thought to result from localized antigen-antibody reactions involving an­
tibody induced by previous vaccination. Therefore, second, or "booster," doses are not  
recommended.
• Vaccine precautions and contraindications
The safety of pneumococcal polysaccharide vaccine in pregnant women has not been 
evaluated. It should not be given to healthy pregnant women. Women at high risk of pneumo­
coccal disease ideally should be vaccinated before pregnancy.
Because of a marked increase in adverse reactions with second injections of pneumococcal 
polysaccharide vaccine, second, or "booster," doses should not be given. However, when 
there is doubt or no information on whether a person in one of the high-risk groups has ever 
received pneumococcal polysaccharide vaccine, vaccine should be given. Complete records 
of vaccination can help to avoid repeat doses.
Typhoid
The occurrence of typhoid fever remained constant in the period 1 9 7 2 -1 9 8 2 , with an 
average of 4 8 6  cases reported annually. During the years 1 9 7 8 -1 9 8 2 , 57% of cases for 
which the patient's age was known occurred in patients 20 years of age or older. Approxi­
mately 62% of typhoid cases reported in the United States during 1 977-1 979 were acquired 
by travelers to other countries, and an additional 27% occurred in contacts of typhoid carriers.
• Typhoid vaccine
A primary series of two 0.5-m l doses of typhoid vaccine given S C  4 weeks apart has been 
shown to protect 70% -90%  of recipients.
• Vaccine indications
Immunization is indicated for travelers to areas where a recognized risk of exposure to ty­
phoid exists. It should be emphasized that even after typhoid vaccination, food and water 
should be selected carefully in these areas. Typhoid vaccination is not recommended in the 
United States or in areas of natural disaster. Booster doses should be given at least every 3 
years to persons with continued or repeated exposure; these may be given S C  (0.5 ml) or ID 
(0.1 ml). The acetone-killed and -dried vaccine should not be given ID. This preparation is 
available only to the U.S. Armed Forces.
• Vaccine side effects and adverse reactions
Typhoid vaccination often results in 1-2 days of discomfort at the site of injection. The 
local reaction may be accompanied by fever, malaise, and headache.
• Vaccine precautions and contraindications
The only contraindication to typhoid vaccine is a history of a severe local or systemic reac­
tion following a previous dose.
Live-Bacteria Vaccines
T u b ercu lo sis
The number of tuberculosis cases in the United States has declined steadily since reporting 
began in the 1 9th century. Between 1 972 and 1 982, the annual incidence of tuberculosis de­
clined from 15.8 cases per 100,000 population to 11.0/100,000, a decrease of 30%. In 
1 982, approximately 92% of 25 ,059  reported cases with patient ages known occurred in per­
sons 20 years of age or older. Reported cases usually are typical postprimary pulmonary dis­
ease. The risk of infection is greatest for those who have repeated exposure to persons with 
unrecognized or untreated sputum-positive pulmonary tuberculosis. In the United States, ef­
forts to control tuberculosis are directed toward early identification and treatment of cases.
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preventive therapy with isoniazid for infected persons at high risk of developing disease, and 
prevention of transmission to others.
• BCG  vaccine
Although BCG vaccine is widely used in many areas of the world, results of a recent large- 
scale field trial in India have raised questions about its efficacy (18) .  BCG vaccines currently 
available in the United States differ from the products used in the published field trials, and 
their efficacy has not been demonstrated directly. In the United States, vaccines for ID and for 
percutaneous administration are licensed. (For percutaneous administration, one drop of vac­
cine is placed on the skin and introduced through the skin by multiple punctures with a 
bifurcated or other needle.) Vaccination should be only by the route indicated on the package 
labeling.
• Vaccine indications
In the United States the only situations in which BCG might be considered are 1) for indi­
viduals in prolonged close contact with patients with active tuberculosis that is untreated, 
ineffectually treated, or resistant to treatment; 2) for health-worker groups, such as hospital 
staffs, with an annual new-infection rate of 1% or higher in spite of other tuberculosis control 
measures; and 3) for other groups in which an excessive rate of new infection can be 
demonstrated and the usual surveillance and treatment programs have failed or are not 
feasible.
* Vaccine side effects and adverse reactions
BCG has been associated with severe or prolonged ulceration at the vaccination site, re­
gional adenitis, disseminated BCG infection, and osteitis. Severe ulceration and adenitis occur 
in approximately 1 % -10% of vaccinees, and disseminated infections and osteitis are quite rare 
(1-10 per million doses).
* Vaccine precautions and contraindications
Although no harmful effects of BCG on the fetus have been observed, it is prudent to 
avoid vaccination during pregnancy unless there is immediate excessive risk of exposure to in­
fective tuberculosis.
Since BCG is a live-bacteria vaccine, it should not be given to persons immunocompro­
mised as a result of immune deficiency diseases, leukemia, lymphoma, or generalized 
malignancy or to persons immunosuppressed as a result of therapy with corticosteroids, 
alkylating drugs, antimetabolites, or radiation. (See "Conditions That Compromise the 
Immune System," page 8S.)
Other Licensed Vaccines
A d e no viru s and  A d e no viru s Vaccine
Adenovirus types 4 and 7 have frequently been the cause of outbreaks of acute, febrile, 
respiratory-tract disease in young adults during military training. Live, oral adenovirus vaccines 
for types 4 and 7 are available for immunization of military populations. Use of the vaccines in 
other populations is not recommended.
A n th ra x  and A n th ra x  Vaccine
Anthrax is infrequently encountered. Anthrax vaccine is recommended only for individuals 
who come in contact with imported animal hides, furs, bonemeal, wool, animal hair (especially 
goat hair), and bristles in the workplace and for individuals undertaking investigational studies 
involving Bacillus anthracis.
Primary immunization consists of six S C  0.5-m l injections, the first three at 2-week inter­
vals and the other three at 6-month intervals. Booster doses of 0.5-m l S C  are recommended 
at 1-year intervals. The vaccine is only available from the Biologic Products Program, Michi­
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gan Department of Public Health. Details on reactions and vaccine contraindications are found 
in the package insert.
P e rtu ss is  and P e rtu ss is  Vaccine
Pertussis disease in adults is generally milder than in children and is not known to result in 
death. Pertussis can be transmitted from adult patients to close contacts, especially unimmu­
nized children. Such transmission may occur in the household and in hospitals, where chains 
of transmission have involved patients and staff.
In general, pertussis vaccine is not recommended for adults because both local and sys­
temic reactions are thought to be more frequent and severe than in children under 7 years of 
age and because the disease itself is less severe in adults. In specific situations, such as docu­
mented transmission to and from personnel in a hospital, single-antigen pertussis vaccine in a 
0.2-m l IM dose has been given as a part of control efforts. Single-antigen pertussis vaccine, 
adsorbed, is available only from the Biologic Products Program, Michigan Department of 
Public Health.
Immune Globulins
IG and specific immune globulins, i.e., HBIG, TIG, HRIG, and varicella zoster immune globulin 
(VZIG), are indicated for use in order to prevent or modify certain diseases in specific 
circumstances.
Im m une G lobulin for In tra m u scu la r U se
IG is given IM for preexposure prophylaxis against hepatitis A to travelers in areas where 
contact with potentially contaminated food and water is unavoidable. For travelers at risk for
2-3 months, a single IM dose of 0 .02 ml/kg is recommended. For more prolonged travel 0.06 
ml/kg should be given every 5 months. IG is also indicated for postexposure prophylaxis for 
close household and sexual contacts of persons with hepatitis A, staff and attendees of day­
care centers and household contacts of diapered children in day-care centers in which hepati­
tis A transmission is occurring, selected staff and clients of custodial institutions in which an 
outbreak is occurring, and co-workers of food handlers with hepatitis A. For such contacts a 
single dose of 0.02 ml/kg of IG is recommended as soon as possible after exposure. IG should 
be given within 2 weeks after exposure.
IG can be used to prevent or modify measles disease in susceptible contacts of persons 
with measles, especially those for whom measles vaccine is contraindicated, if given within 6 
days after exposure. The recommended dose is 0.25 ml/kg (maximum dose =  15 ml). IG 
should not be used to control measles outbreaks.
Im m une Globulin for In tra veno u s U se
IG modified for IV administration may be given to prevent acute infections in patients with 
defective antibody synthesis or as prophylaxis against hepatitis A for patients for whom the 
IM preparation is contraindicated because of thrombocytopenia or disorders that can cause 
IM hemorrhage. ONLY IG MODIFIED FOR INTRAVENOUS USE CAN BE GIVEN INTRAVE­
NOUSLY. The IV dose is 100 mg/kg, given slowly. The IV preparation is supplied in 50-m l 
vials containing 2.5 g of IG.
H e p a titis  B  Im m une Globulin
HBIG, alone or in combination with HB vaccine, is used for postexposure prophylaxis of 
HBV infection. For percutaneous or mucous membrane exposure to blood known to be HBsAg
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positive or from a bite by an HBV carrier, a single dose of HBIG (0.06 ml/kg or 5 ml for adults) 
should be given as soon as possible, and a series of three doses of HB vaccine begun within 1 
week after exposure. Vaccine and HBIG may be given simultaneously, but in different sites. 
For those who choose not to take HB vaccine, a second identical dose of HBIG should be 
given 1 month later.
Following percutaneous exposure to blood from individuals at high risk of being HBsAg 
positive (such as persons with acute, unconfirmed viral hepatitis) or from patients at high risk 
of being infected with hepatitis B (such as male homosexuals, users of illicit IV drugs, and 
hemodialysis patients), IG should be given immediately to the exposed person as an IM dose 
of 0.06 ml/kg. Then serologic confirmation of the HBsAg status of the suspected high-risk 
patient should be obtained as soon as possible, and certainly within 7 days. If the suspected 
high-risk patient is HBsAg positive, the exposed person should immediately receive HBIG and 
hepatitis B vaccine according to the schedule above. The value of HBIG given beyond 7 days 
after exposure is unclear.
For homosexual exposure to HBsAg-positive males (known carriers or persons with acute 
cases), a single dose of HBIG should be given to susceptible contacts within 1 4 days after the 
last sexual exposure. Since HB vaccine is routinely recommended for male homosexuals, an 
HB vaccine series should be started within 7 days after HBIG administration.
For heterosexual exposures to persons with acute cases of hepatitis B, a single dose of 
HBIG (0.06 ml/kg or 5 ml for adults) should be given within 14 days of the last sexual contact. 
If the index case remains HBsAg positive at 3 months and exposure continues, the contact 
should be given a second dose of HBIG. If the index case becomes an HBV carrier (HGsAg 
positive for 6 months), the HB vaccine series should be given to the contact.
Tetanus Im m une Globulin
TIG is indicated in tetanus prophylaxis as part of the management of wounds other than 
clean, minor wounds in persons 1) whose previous tetanus toxoid immunization status is un­
known or uncertain, 2) who have received fewer than two previous tetanus toxoid doses, or
3) who have received only two previous tetanus toxoid doses and whose wound is more than 
24 hours old. The currently recommended prophylactic dose for wounds of average severity 
is 25 0  units IM Td should be given at the same time but at a separate site.
A summary of the indications for active and passive immunization in the management of 
wounds is provided in Table 5.
Hum an R a b ie s Im m une G lobulin
Postexposure prophylaxis for rabies should always include HRIG with one exception: per­
sons who have been previously immunized with the recommended preexposure or postexpo­
sure regimens of HDCV or have been immunized with other types of rabies vaccines and have 
a history of documented adequate rabies antibody titer should not receive HRIG (Table 4). 
The recommended dose of HRIG is 20  Ill/kg body weight. If anatomically feasible, up to one- 
half the dose of HRIG should be thoroughly infiltrated in the area around the wound, the rest 
should be administered IM.
V a rice lla -Z o ste r Im m une Globulin
Most adults (85%-95%) with negative or unknown histories of varicella disease (chicken- 
pox) are likely to be immune. (Susceptibility rates for adults raised in some tropical areas, par­
ticularly remote areas, may be somewhat higher.) Rates of complications and death for immu­
nocompromised adults who contract varicella are likely to be substantially greater than for
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normal adults. After careful, individual evaluation, an immunocompromised patient who is be­
lieved to be susceptible and who has had significant exposure to varicella should receive 
VZIG to prevent complications.
Significant exposure to a person with varicella includes household contact, close contact 
indoors of longer than 1 hour, sharing the same two- to four-bed hospital room, or prolonged, 
direct, face-to-face contact such as occurs with nurses or doctors who take care of the 
patient.
Chickenpox can be more severe in adults than in normal children. The decision to adminis­
ter VZIG  to a normal adult should be made on an individual basis. The objective of VZIG  use 
for normal adults is to modify rather than prevent illness in hopes of inducing lifelong immuni­
ty. When deciding whether to administer VZIG, the clinician should consider the patient's 
health status, the type of exposure, and the likelihood of previous infection. It is likely that 
adults who were older siblings in large families or whose children have had varicella are 
immune. If, after careful evaluation, a normal adult with significant exposure to varicella is be­
lieved to be susceptible, VZIG  may be administered. Pregnant women and potentially sus­
ceptible hospital personnel should be evaluated in the same way as other adults. Supplies of 
VZIG  are limited, and indiscriminate administration of VZIG  to normal adults would quickly ex­
haust supplies and prevent prophylaxis for known high-risk individuals. The cost of a five-vial 
adult dose is approximately $375 .
VZIG, available through some American Red Cross distribution centers (Appendix 5), is 
supplied in vials containing 1 25 units. W hereas 1 25 units/1 0 kg of body weight up to a maxi­
mum of 625 units generally is considered likely to prevent or modify varicella in normal 
adults, higher doses may be necessary for the immunocompromised adult. However, the ap­
propriate dose for immunocompromised adults has not been determined. VZIG  should be ad­
ministered IM as directed by the manufacturer. While the duration of protection is unknown, it 
seems reasonable that protection should last for at least one half-life of the immune globulin, 
that is, approximately 3 weeks.
Im m une G lobulin  S id e  E f fe c t s  and  A d v e rse  R e a ctio n s
Serious adverse effects have been rare from immune globulins administered as 
recommended.
Im m une G lobulin  P re ca u tio n s and C o n tra in d ica tio n s
Immune globulins, if needed, are not contraindicated for pregnant women. Except for the 
IV preparation of IG, immune globulins are prepared for IM use and should not be given IV. 
The various preparations intended for IM use should not be given to patients with severe 
thrombocytopenia or other coagulation disorders that would ordinarily contraindicate IM in­
jections unless the expected benefits outweigh the risks.
Parenterally administered live-virus vaccines (e.g., MMR or other combinations) should be 
given at least 1 4 days before or at least 6 weeks, and preferably 3 months, after the adminis­
tration of immune globulins. If an immune globulin must be administered within 14 days after 
the administration of most live-virus vaccines, the vaccine should be administered again 3 
months after the immune globulin is given. If the interval between vaccine receipt and immune 
globulin receipt is longer, the vaccine need not be readministered.
Preliminary data indicate that immune globulins do not interfere with the immune response 
to either OPV or yellow fever vaccine.
In Ju ly 1983, a WHO Consultative Group reviewed data on both normal and specific 
immune globulins prepared from plasma collected mainly in the United States, including dona­
Vol. 33/No. 1S MMWR 37S
tions from homosexuals. The data indicated that although about 19.5 million 2-ml to 10-ml 
doses of immune globulin had been prepared during the preceding 4 years, no transmission of 
hepatitis B or any other infectious agents and no cases of A ID S had been reported in persons 
observed for 1-4 years after receiving immune globulin. Therefore, the Consultative Group 
confirmed that, at present, there is no evidence of risk attached to the use of normal or specif­
ic immune globulins prepared by the universally accepted methods ( 19).
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TABLE 1. Vaccines and toxoids recommended for adults in general, by age groups
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Age group
Vaccine or toxoid
Td* M easles Mumps Rubella Influenza
Pneum ococcal
polysaccharide
1 8 -2 4  years X X X
2 5 -6 4  years X X+ x§ xli
S=65 years X X X
N OTE: Refer to text on specific vaccines or toxoids for indications, contraindications, precautions, d os­
ages, side effects and adverse reactions, and special considerations.
"Diphtheria and tetanus toxoids adsorbed (for adult use), Td, a combined preparation containing less 
than 2 Lf of diphtheria toxoid.
^Indicated for persons born after 1956.
^Indicated especially for susceptible males.
Principally recommended for females up to 45 years of age
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TABLE 2. Immunobiologies recommended for special occupations, lifestyles, environ­
mental circum stances, travel, foreign students, immigrants, and refugees*
Indication Im m unobiologic(s)
Occupation
Hospital, laboratory, and other Hepatitis B
health care personnel Polio
Influenza
Staff of institutions for the mentally retarded Hepatitis B
Veterinarians and animal handlers Rabies
Selected field workers Plague
Lifestyles
Homosexual males Hepatitis B
Illicit drug users Hepatitis B
Environmental situation
Inmates of long-term correctional facilities Hepatitis B
Residents of institutions for the Hepatitis B
mentally retarded
Travel Measles
Rubella
Polio
Yellow fever 
Hepatitis B 
Rabies
M eningococcal polysaccharide
Typhoid
Cholera
Plague
Immune globulin
Foreign students, immigrants, and refugees Measles
Rubella
Diphtheria
Tetanus
N O TE: Refer to text on specific vaccines or toxoids for use by specific risk groups, details on indications, 
contraindications, precautions, dosages, side effects and adverse reactions, and special considerations. 
"Unless specifically contraindicated, the vaccine or toxoids generally recommended for adults are also in­
dicated. Table 1 show s vaccines and toxoids appropriate for age for most adults.
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TABLE 3. Vaccines and toxoids indicated or specifically contraindicated for special 
health status situations*
Vaccines or toxoids
Health situations Indicated Contraindicated
Pregnancy Diphtheria and tetanus 
toxoids (Td)
Uve-virus vaccines
Immunocompromised Influenza
Pneumococcal polysaccharide
Live-virus vaccines
Splenic dysfunction, 
anatomic asplenia
Influenza
Pneumococcal polysaccharide
Hemodialysis Hepatitis B (double dose) 
Influenza
Pneumococcal polysaccharide
Deficiencies of 
factors VIII or IX
Hepatitis B
Chronic alcoholism Pneumococcal polysaccharide
Diabetes and other high­
risk diseases
Influenza
Pneumococcal polysaccharide
N OTE: Refer to text on specific vaccines or toxoids for details on indications, contraindications, precau­
tions, dosages, side effects and adverse reactions, and special considerations.
'Unless specifically contraindicated, the vaccines and toxoids generally recommended for adults are 
also indicated. Table 1 show s vaccines and toxoids appropriate for age for most adults.
TA BLE 4. Immunobiologies and schedules for adults (18 years of age and older)*^
Im m unobiologic  
generic name
Primary schedule and 
booster(s) Indications
Major precautions.and 
contraindications 3 Special considerations
T O X O ID S
Tetanus-diphtheria 
toxoid (Td)
2 doses intramuscularly 
(IM) 4 weeks apart; 3rd 
dose 6-1 2 months after 
2nd dose; booster every 
10 years
All adults Except in the first trimester, 
pregnancy is not a contra­
indication. History of a 
neurologic reaction or 
immediate hypersensitivity 
reaction following a pre­
vious dose. History 
of severe local reaction 
(Arthus-type) following 
previous dose. Such 
individuals should not be 
given further routine or 
emergency doses of Td for 
10 years.
Tetanus prophylaxis in wound 
management (summarized in text 
on page 11S  and in Table 5)
LIV E -V IR U S  V A CCIN ES
Measles live-virus 1 dose subcutaneously 
vaccine (SC); no booster
All adults born after 
1956 without documen­
tation of live vaccine 
on or after 1 st birthday 
or physician-diagnosed 
measles or laboratory 
evidence of immunity; 
persons born before 1957 
are generally con­
sidered immune. Su scep ­
tible travelers
Pregnancy; immunocompromised 
persons'1; history 
of anaphylactic 
reactions following 
egg ingestion or receipt 
of neomycin (see text)
Measles, mumps, rubella vaccine 
(MMR) is the vaccine of choice if 
recipients are likely to be suscep­
tible to rubella and/or mumps as 
well as to measles. Persons vacci­
nated between 1 963 and 1967 
with a killed-measles vaccine, 
followed by live vaccine within 
3 months or with a vaccine of 
unknown type should be revac­
cinated with live-measles-virus 
vaccine.
Mumps live-virus 
vaccine
1 dose S C ; 
booster
All adults, particularly 
males, believed to be 
susceptible can be 
vaccinated. Most adults 
can be considered 
immune.
Pregnancy, immunocompromised 
persons^1; history 
of anaphylactic reaction 
following egg ingestion 
or receipt of neomycin 
(see text)
MMR is the vaccine of choice if 
recipients are likely to be 
susceptible to measles and 
rubella as well as to mumps.
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Rubella live-virus 
vaccine
1 dose S C , no 
booster
Indicated for adults, 
both male and female, 
lacking documentation of 
live vaccine on or after 
1 st birthday or laboratory 
evidence of immunity, par­
ticularly women of child­
bearing age and young 
adults who work or congre­
gate in places such as 
hospitals, colleges, and 
the military. Susceptible 
travelers
Pregnancy; immunocompromised 
persons^; history of 
anaphylactic reaction 
following receipt of 
neomycin
Women pregnant when vaccinated 
or who become pregnant within 
3 months of vaccination should 
be counseled on the theoretical 
risks to the fetus. The risk of 
rubella vaccine-associated 
malformations in these women 
is so small as to be negligible.
MMR is vaccine of choice if 
recipients are likely to be 
susceptible to measles or mumps 
as well as to rubella.
Sm allpox vaccine 
(vaccinia virus)
Yellow fever live, 
attenuated virus 
(1 7D strain)
THERE A RE NO IN DICATIONS FOR THE U SE OF SM A LLP O X  VACCINE IN THE GENERAL 
CIVILIAN POPULATION.
1 dose S C  6 days 
to 10 years before 
travel; booster every 
10 years
Selected persons travel­
ing or living in areas 
where yellow fever 
infection exists.
Although specific 
information is not available 
concerning adverse effects 
on the developing fetus,
Laboratory workers involved with 
orthopox virus or in the production 
and testing of smallpox vaccines 
should receive regular smallpox 
vaccinations. For advice on vac­
cine administration and 
contraindications, contact the 
International Health Program 
Office, CD C, Atlanta, Georgia 
30333.
Som e countries require a valid 
International Certification of 
Vaccination showing receipt of 
vaccine.
"Several other vaccines, toxoids, and immune globulins are licensed and available. These are noted in Appendix 3. In addition, the following antitoxins are 
licensed and available: (1) botulism antitoxin, trivalent (ABE) equine (distributed by CD C only), (2) tetanus antitoxin (equine), (3) diphtheria antitoxin 
(equine), and (4) rabies antitoxin (equine).
^Several vaccines and toxoids are in "Investigation of New Drug" (IND) status and available only through the Division of Host Factors, Center for Infectious 
Disease, CDC. These are: (1) pentavalent (ABCDE) botulinum toxoid, (2) eastern equine encephalitis (EEE) vaccine, (3) Venezualan equine encephalitis 
(VEE) vaccine, and (4) tularemia vaccine
§When any vaccine or toxoid is indicated during pregnancy, waiting until the second or the third trimester, when possible, is a reasonable precaution that 
minimizes concern about teratogenicity.
^Persons immunocompromised because of immune deficiency diseases, leukemia, lymphoma or generalized malignancy or immunosuppressed as a 
result of therapy with corticosteroids, alkylating drugs, antimetabolites or radiation.
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Imm unobiologic Primary schedule and
generic name booster(s) Indications
Major precautions,and  
contraindications^ Special considerations
L IV E -V IR U S  AND IN A CTIV A TED -V IRU S V A CCIN ES
Polio vaccines: 
Killed-poliovirus 
vaccine (IPV) 
Live-poliovirus 
vaccine (OPV)
IPV preferred for 
primary vaccination;
3 doses S C  4 weeks 
apart; a 4th dose 
6-1 2 months after 3rd; 
for adults with a com ­
pleted primary series 
and for whom a booster 
is indicated, either 
O PV or IPV can be given. 
If immediate protect­
io n  is needed, OPV 
is recommended.
Persons traveling to 
areas where wild 
poliovirus is epidemic 
or endemic and certain 
health-care personnel 
(see text for 
recommendations for 
incompletely immunized 
adults and adults 
in households of children 
to be immunized).
f
it is prudent on theoretical 
grounds to avoid vaccinating 
pregnant women unless the 
individual must travel to 
areas where the risk of 
yellow fever is high. 
Immunocompromised persons; 
history of hypersensitivity 
to egg ingestion
Although there is no con­
vincing evidence document­
ing adverse effects of 
either OPV or IPV on the 
pregnant woman or develop­
ing fetus, it is prudent 
on theoretical grounds to 
avoid vaccinating pregnant 
women. However, if immediate 
protection against poliomyeli­
tis is needed, OPV is 
recommended.
OPV should not be given to 
immunocompromised individuals 
or to persons with known or 
possibly immunocompromised 
family members.^ IPV is 
recommended in such 
situations.
If the only reason to vaccinate 
a pregnant woman is an interna­
tional requirement, efforts should 
be made to obtain a waiver letter 
(see page 19S).
Although a protective immune 
response to IPV in the 
immunocompromised 
individual cannot be assured, 
the vaccine is safe and some 
protection may result from 
its administration.
IN A CTIV A TED -V IR U S V A CCIN ES
Hepatitis B (HB) 2 doses IM 4 weeks
inactivated-virus apart; 3rd dose 5 months
vaccine after 2nd; need for
boosters unknown
Adults at increased 
risk of occupational, 
environmental, social, 
or family exposure
Data are not available on 
the safety of the vaccine 
for the developing fetus. 
Because the vaccine
The vaccine produces neither 
therapeutic nor adverse effects 
on HBV-infected persons. 
Prevaccination serologic
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contains only noninfectious 
hepatitis B surface antigen 
particles, the risk should 
be negligible. Pregnancy 
should not be considered 
a vaccine contraindication 
if the woman is otherwise 
eligible.
screening for susceptibility 
before vaccination may or may 
not be cost effective depending 
on costs of vaccination and 
testing and on the prevalence 
of immune individuals in the 
group.
Influenza vaccine 
(inactivated whole- 
virus and split­
virus) vaccine
Annual vaccination with 
current vaccine.
Either whole- or 
split-virus vaccine 
may be used.
Human diploid cell 
rabies vaccine 
(HDCV) (inacti­
vated, whole-virion 
and subvirion)
Preexposure pro­
phylaxis. 2 doses 1 week 
apart; 3rd dose 3 weeks 
after 2nd; if exposure 
continues, booster doses 
every 2 years, or an an­
tibody titer determined
Adults with high-risk 
conditions, residents of 
nursing homes or other 
chronic-care facilities, 
medical-care personnel, 
healthy persons 
over 65.
Veterinarians, animal 
handlers, certain lab­
oratory workers, and 
persons living in or 
visiting countries for 
>  1 month where 
rabies is a constant
Although no evidence 
exists of maternal or 
fetal risk when vaccine is 
given in pregnancy because 
of an underlying high-risk 
condition in a pregnant 
woman, waiting until the 
second or third trimester, if 
possible, is reasonable. History of 
anaphylactic hypersensitivity 
to egg ingestion
If there is substantial 
risk of exposure to rabies, 
preexposure vaccination may 
be indicated during 
pregnancy. Corticosteroids 
and immunosuppressive 
agents can interfere with
Complete preexposure 
prophylaxis does not eliminate 
the need for additional therapy 
with rabies vaccine after a rabies 
exposure. The Food and Drug 
Administration has not approved 
the intradermal (ID) use of HDCV.
'Several other vaccines, toxoids, and immune globulins are licensed and available. These are noted in Appendix 3. In addition, the following antitoxins are 
licensed and available: (1) botulism antitoxin, trivalent (ABE) equine (distributed by CDC only), (2) tetanus antitoxin (equine), (3) diphtheria antitoxin 
(equine), and (4) rabies antitoxin (equine).
^Several vaccines and toxoids are in "Investigation of New Drug” (IND) status and available only through the Division of Host Factors, Center for Infectious 
Disease, CDC. These are: (1) pentavalent (ABCDE) botulinum toxoid, (2) eastern equine encephalitis (EEE) vaccine, (3) Venezualan equine encephalitis 
(VEE) vaccine, and (4) tularemia vaccine
§When any vaccine or toxoid is indicated during pregnancy, waiting until the second or the third trimester, when possible, is a reasonable precaution that 
minimizes concern about teratogenicity.
Persons immunocompromised because of immune deficiency diseases, leukemia, lymphoma or generalized malignancy or immunosuppressed as a 
result of therapy with corticosteroids, alkylating drugs, antimetabolites or radiation.
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Imm unobiologic 
generic name
Primary schedule and 
booster(s) Indications
Major precautions^and 
contraindications * Special considerations
and a booster dose given threat 
if titer inadequate ( <  5)
Postexposure prophylaxis:
All postexposure treat­
ment should begin with 
immediate cleansing of 
the wound with soap and 
water.
(1) Persons who have 
a) previously received 
postexposure prophylaxis 
with HDCV, b) received 
recommended IM pre­
exposure series of HDCV,
c) received recommended 
ID preexposure series of 
HDCV in the U.S., or
d) have a previously doc­
umented rabies antibody 
titer considered ade­
quate: 2 doses of HDCV,
1.0 ml IM, one each on 
days 0  and 3
(2) Persons not previously 
immunized as above: HRIG 
20 international units 
(IU)/kg body weight,
half infiltrated at bite 
site if possible, remainder 
IM; and 5 doses of HDCV,
1.0 ml-IM, one each on 
days 0, 3, 7, 1 4 ,2 8
the development of active 
immunity; history of 
anaphylactic or Type III 
hypersensitivity reaction 
to previous dose of HDCV 
(See text).
Recommendations for the ID use 
of HDCV are currently being 
discussed. Suggestions 
concerning ID use of HDCV for 
preexposure prophylaxis are 
found on page 2 6 S  and in CDC. 
Rabies Prevention — United 
States, 1 984. MMWR 1 984;33: 
39 3 -4 0 2 ,4 0 7 -8 .
The decision for postexposure 
use of HDCV depends on the 
species of biting animal, the cir­
cumstances of biting incident, and 
the type of exposure (i.e. bite.sali- 
va contamination of wound, etc.). 
The type of and schedule for 
post-exposure prophylaxis 
depends upon the person's 
previous rabies vaccination 
status, or the result of a previous 
or current serologic test for 
rabies antibody. For post­
exposure prophylaxis, HDCV 
should always be 
administered IM, not ID.
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IN A CTIV A TED -B A CTER IA  V A CCIN ES
Cholera vaccine Two 0.5-m l doses S C  or 
IM or two 0.2-m l doses 
ID 1 week to 1 month 
apart; booster doses 
(0.5 ml IM or 0.2 ml ID) 
every 6 months
Meningococcal 
polysaccharide 
vaccines 
(bivalent A and C 
and tetravalent 
A, C, W 135 , and Y)
Plague vaccine
1 dose in volume and 
by route specified 
by manufacturer; need 
for boosters unknown
3 IM doses; first 
dose 1.0 ml; 2nd 
dose 0.2 ml 1 month 
later; 3rd dose 
0.2 ml 5 months after 
2nd; booster doses 
(0.2 ml) at 1 -2 year 
intervals if exposure 
continues
Travelers to countries 
requiring evidence of 
cholera vaccination for 
entry
Travelers visiting 
areas of a country 
that are recognized 
as having epidemic 
m eningococcal disease
Selected travelers to 
countries reporting 
cases, for whom avoidance 
of rodents and fleas is 
impossible; all labora­
tory and field personnel 
working with Yersinia 
pestis  organisms possi­
bly resistant to anti­
microbials; those 
engaged in X pestis  
aerosol experiments or 
in field operations 
in areas with enzootic
No specific information on 
vaccine safety during 
pregnancy. Use in pregnancy 
should reflect actual 
increased risk. Persons 
who have had severe local 
or system ic reactions to a 
previous dose
Pregnancy, unless there is 
substantial risk of 
of infection
Pregnancy, unless there is 
substantial and unavoidable 
risk of exposure; persons 
with known hypersensitivity 
to any of the vaccine con­
stituents (see manufacturer's 
label); patients who have had 
severe local or system ic 
reactions to a previous dose
One dose generally satisfies 
International Health Regulations. 
Som e countries may require 
evidence of a complete primary 
series or a booster dose given 
within 6 months before arrival. 
Vaccination should not be 
considered as an alternative to 
continued careful selection of 
foods and water.
Prophylactic antibiotics may be 
recommended for definite 
exposure whether or not the 
exposed persons has been 
vaccinated.
"Several other vaccines, toxoids, and immune globulins are licensed and available. These are noted in Appendix 3. In addition, the following antitoxins are 
licensed and available: (1) botulism antitoxin, trivalent (ABE) equine (distributed by CDC only), (2) tetanus antitoxin (equine), (3) diphtheria antitoxin 
(equine), and (4) rabies antitoxin (equine).
^Several vaccines and toxoids are in "Investigation of New Drug" (IND) status and available only through the Division of Host Factors, Center for Infectious 
Disease, CDC. These are: (1) pentavalent (ABCDE) botulinum toxoid, (2) eastern equine encephalitis (EEE) vaccine, (3) Venezuelan equine encephalitis 
(VEE) vaccine, and (4) tularemia vaccine
§When any vaccine or toxoid is indicated during pregnancy, waiting until the second or the third trimester, when possible, is a reasonable precaution that 
minimizes concern about teratogenicity.
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Im m unobiologic Primary schedule and 
generic name booster(s) Indications
Major precautions.and 
contraindications* Special considerations
Pneumococcal 
polysaccharide 
vaccine (23 valent)
1 dose, booster not 
recommended
plague where regular 
exposure to potentially 
infected wild rodents, rab­
bits, or their fleas 
cannot be prevented
Adults who are at 
increased risk of pneu­
m ococcal disease and its 
complications because of 
underlying health condi­
tions; older adults, 
especially those age 65 
and over, who are 
healthy
The safety of vaccine in 
pregnant women has not been 
evaluated; it should not be 
given during pregnancy unless 
the risk of infection is 
high. Previous recipients of 
any type of pneumococcal 
polysaccharide vaccine 
should not receive 
another dose of vaccine
Typhoid vaccine Two 0.5-m l doses S C  
4 or more weeks apart, 
booster 0.5 ml S Q  or 
0.1 ml ID every 3 years 
if exposure continues
Travelers to areas 
where there is a 
recognized risk of 
exposure to typhoid
Severe local or system ic 
reaction to a previous 
dose. Acetone killed and 
dried vaccines should not 
be given ID.
Vaccination should not be 
considered as an alternative 
to continued careful selection 
of foods and water.
L IV E -B A C T E R IA  VA CCIN E
BCG 1 ID or S C  dose (see
package label)
IM M U N E G LO B U LIN S
Immune globulin Hepatitis A prophylaxis:
(IG) Preexposure-1 IM dose
Prolonged close contact 
with untreated or in­
effectively treated 
active tuberculosis 
patients; groups with 
excessive rates of new 
infection in which other 
control measures have not 
been successful
Household and sexual con­
tacts of persons with
Pregnancy, unless there is 
unavoidable exposure to 
infective tuberculosis; 
immunocompromised 
patients
In the United States tuberculosis 
control efforts are directed toward 
early identification, treatment of 
cases and preventive therapy with 
isoniazid.
For travelers IG is not an 
alternative to continued
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of 0.02 ml/kg for anti­
cipated risk of 2-3  
months; IM dose of 0.06 
ml/kg for anticipated 
risk of 5 months; repeat 
appropriate dose at 
above intervals if 
exposure continues.
hepatitis A; travelers to 
high-risk areas outside 
tourist routes; staff, 
attendees, and parents 
of diapered attendees 
in day-care-center 
outbreaks
careful selection of foods 
and water. Frequent travelers 
should be tested for hepatitis 
antibody.
Postexposure-1 IM 
dose of 0.02 ml/kg 
given within 2 weeks 
of exposure
Measles prophylaxis: 
0.25 ml/kg IM (maximum 
1 5 ml) given within 
6 days after exposure
Exposed susceptible 
contacts of measles 
cases
IG should not be used 
to control measles
IG given within 6 days after 
exposure can prevent or 
modify measles. Recipients of 
IG for measles prophylaxis 
should receive live-measles 
vaccine 3 months later.
Hepatitis B immune 0.06 ml/kg IM as soon
globulin (HBIG) as possible after 
exposure followed by a 
second dose 1 month 
later except when HB 
vaccine is given
Following percutaneous 
or mucous membrane 
exposure to blood known 
to be HBsAg positive; 
following sexual exposure 
to or a bite from a 
person with acute HBV 
or an HBV carrier.
IG (0.06 ml/kg) may be used 
if HBIG is not available.
'Several other vaccines, toxoids, and immune globulins are licensed and available. These are noted in Appendix 3. In addition, the following antitoxins are 
licensed and available: (1) botulism antitoxin, trivalent (ABE) equine (distributed by CD C only), (2) tetanus antitoxin (equine), (3) diphtheria antitoxin 
(equine), and (4) rabies antitoxin (equine).
^Several vaccines and toxoids are in "Investigation of New Drug” (IND) status and available only through the Division of Host Factors, Center for Infectious 
Disease, CDC. These are: (1) pentavalent (ABCDE) botulinum toxoid, (2) eastern equine encephalitis (EEE) vaccine, (3) Venezualan equine encephalitis 
(VEE) vaccine, and (4) tularemia vaccine
§When any vaccine or toxoid is indicated during pregnancy, waiting until the second or the third trimester, when possible, is a reasonable precaution that 
minimizes concern about teratogenicity.
^Persons immunocompromised because of immune deficiency diseases, leukemia, lymphoma or generalized malignancy or immunosuppressed as a 
result of therapy with corticosteroids, alkylating drugs, antimetabolites or radiation
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Im m unobiologic 
generic name
Prim ary schedule  and 
booster(s)
Major precautions and 
Indications contraindications^ Specia l considerations
Tetanus immune 
globulin (TIG)
250 units IM Part of management of 
nonclean, nonminor wound 
in a person with unknown 
tetanus toxoid status, with 
less than two previous 
doses, or with two 
previous doses and a 
wound more than 
24 hours old.
Rabies immune 
globulin, human 
(HRIG)
20  lU/kg, up to half 
infiltrated 
around wound, 
remainder IM
Part of management of 
rabies exposure in persons 
lacking a history of recom­
mended preexposure or 
postexposure prophylaxis 
with HDCV
Although preferable to be given 
with the 1 st dose of vaccine, 
can be given up to the 
8th day after the 1 st dose 
of vaccine.
Varicella-zoster 
immune globulin 
(VZIG) '
Persons ^  50  kg:
125 units/10kg IM; 
persons >  50 kg: 
625 un its"
Immunocompromised patients 
known or likely to be su s­
ceptible with close and pro­
longed exposure to a house­
hold contact case or to an 
infectious hospital staff 
member or hospital roommate.^
NOTE: Refer to text on specific vaccines or toxoids for further details on indications, contraindications, precautions, dosages, side effects, and adverse 
reactions, and special considerations and individual ACIP statements (see list of published ACIP statements in Appendix 2).
‘ Several other vaccines, toxoids, and immune globulins are licensed and available. These are noted in Appendix 3. In addition, the following antitoxins are 
licensed and available: (1) botulism antitoxin, trivalent (ABE) equine (distributed by CDC only), (2) tetanus antitoxin (equine), (3) diphtheria antitoxin 
(equine), and (4) rabies antitoxin (equine).
^Several vaccines and toxoids are in "Investigation of New Drug" (IND) status and available only through the Division of Host Factors, Center for 
Infectious Disease, CDC. These are: (1) pentavalent (ABCDE) botulinum toxoid, (2) eastern equine encephalitis (EEE) vaccine, (3) Venezualan equine 
encephalitis (VEE) vaccine, and (4) tularemia vaccine
§When any vaccine or toxoid is indicated during pregnancy, waiting until the second or the third trimester, when possible, is a reasonable precaution that 
minimizes concern about teratogenicity.
^ Persons immunocompromised because of immune deficiency diseases, leukemia, lymphoma or generalized malignancy or immunosuppressed as a 
result of therapy with corticosteroids, alkylating drugs, antimetabolites or radiation.
" S o m e  p e rs o n s  h a v e  re c o m m e n d e d  A 2 b  un\\s/AO V.g re g a rd le ss  ol \o ta \  b o d v  'wevqjht.
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TA B LE  5. Sum m ary guide to tetanus prophylaxis in routine wound management
Vol. 33/No. 1S  MMWR 5 1S
H istory of
tetanus
im m unization
Clean, m inor 
w ounds
All other 
w ounds
Td* t i g t Td* T IG 1
Uncertain Yes No Yes Yes
0-1 Yes No Yes Yes
2 Yes No Yes NoS
3 or more No'1 No N o " No
N O TE: Refer to text on specific vaccines or toxoids for contraindications, precautions, dosages, side ef­
fects and adverse reactions, and special considerations. Important details are in the text and ACIP recom­
mendation (MMWR 1 981; 30 :3 9 2 -4 0 7 ).
"The combined preparations Td, containing both tetanus and diphtheria toxoids, is preferred to tetanus 
toxoid alone.
^Tetanus immune globulin.
§Yes, if wound more than 24 hours old.
 ^Yes, if more than 10 years since last dose.
" Y e s , if more than 5 years since last dose (more frequent boosters are not needed and can accentuate 
side effects.)
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A P P EN D IX  1. Suggested immunization record form
N am e _________________________  S e x _________  Birthdate
VACCIN E
VACCIN E
T Y P E
DATE G IVEN  
M O/DAY/YR
VA CCIN E  
LOT # D O CTO R OR C L IN IC
DATE 
D O SE DUE
POLIO
OPV
or
IPV
(specify  
type used)
DTP
(diphtheria
tetanus
pertussis)
DT
(Pediatric)
or
Td (Adult) 
(specify  
type used)
M E A S L E S  
M U M PS  
R U B E LLA  or 
Com binations 
(MMR,
m easles-rubella, 
rubella-m um ps) 
(specify  
type used)
O TH ER  
vaccin es or 
immune 
globulins 
(specify  
type used)
T U B E R C U LIN
T E S T
N O T ES:
A P P EN D IX  2. Published ACIP statem ents* (as of Ju ne  30. 1984)
Vol. 33/No. 1S MMWR 53S
T itle  of A C IP  Statem en t M M W R  Publication
General recommendations on immunizations 1 9 8 3 :3 2 :1 -8 ,1 3 -7
Diphtheria, tetanus, and pertussis. 1 9 8 1 :3 0 :3 9 2 -9 6 ,4 0 1 -7
guidelines for vaccine prophylaxis and Erratum. 1 981 ;30 :420
other preventive measures
Measles prevention 1 982;31 :21  7-24 ,229 -31
Mumps vaccine 1 9 8 2 :3 1 :6 1 7 -2 0 ,6 2 5
Rubella prevention 1 9 8 4 :3 3 :3 0 1 -1 0 ,3 1 5 -8
Yellow fever vaccine 1 9 8 4 :3 2 :6 7 9 -8 2 ,6 8 7 -8
Poliomyelitis prevention 1 982;31 22-6,31 -4
Prevention and control of influenza* 1 9 8 4 :3 3 :2 5 3 -6 0 ,2 6 5 -6
Inactivated hepatitis B virus vaccine 1 9 8 2 :3 1 :3 1 7 -2 2 ,3 2 7 -8
Postexposure prophylaxis of hepatitis B 1 9 8 4 :3 3 :2 8 5 -9 0
Rabies prevention
Supplementary statement on rabies
vaccine and serologic testing 1 9 8 1 ;3 0 :5 3 5 -6
Rabies 1 9 8 4 ;3 3 :3 9 3 -4 0 2 ,4 0 7 -8
Supplementary statement on 1 9 8 2 :3 1 :2 7 9 -8 0 ,2 8 5
pre-exposure rabies prophylaxis by
the intradermal route
Cholera vaccine 1 9 7 8 :2 7 :1 7 3 -4
Meningococcal polysaccharide vaccine 1 9 7 8 :2 7 :3 2 7 -9
Plague vaccine 1 9 8 2 ;3 1 :3 0 1 -4
Update: Pneum ococcal polysaccharide vaccine 1 9 8 4 :3 3 :2 7 3 -6 ,8 1
usage —United States
Typhoid vaccine 1 9 7 8 ;2 7 :2 3 1 -3
BCG vaccines 1 9 7 9 ;2 8 :2 4 1 -4
Immune globulins for protection against
viral hepatitis 1 9 8 1 :3 0 :4 2 3 -8 ,4 3 3 -5
Varicella-zoster immune globulin for the
prevention of chickenpox 1 9 8 4 :3 3 :8 4 -9 0 ,9 5 -1 0 0
'Th e  Immunization Practices Advisory Committee (ACIP) periodically reviews recommendations on va c­
cination and prophylaxis. When recommendations are revised, they are published individually in the 
MMWR.
^Each year influenza vaccine recommendations are reviewed and amended to reflect updated informa­
tion on influenza activity in the United States for the preceding influenza season and to provide informa­
tion on the vaccine available for the upcoming influenza season. These recommendations are published 
in the MMWR annually, usually during June or July.
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A P P E N D IX  3. Im m u n o b io lo g ie s  a v a ila b le  a s  of Ju n e
d u c t  n a m e
3 0 . 1 9 8 4 , b y  m a n u fa c tu re r  and pro-
Im munobiologic M anufacturer Product Name
Adenovirus vaccine
Anthrax vaccine
W yeth Labs, Inc
Biol Prods Program, 
Michigan Dept of 
Public Health
Adenovirus, Live, Oral, Type 4* 
Adenovirus, Live, Oral, Type 7*
Anthrax Vaccine Adsorbed
BCG vaccine Glaxo Operations UK 
Limited
BCG Vaccine
Cholera vaccine
Diphtheria and tetanus 
toxoids adsorbed
Inst Tuberculosis 
Research, Univ Of 
Illinois at Chicago
Lederle Laboratories,
Div American Cyanamid Co
W yeth Labs, Inc
Sciavo  SpA *
Lederle Laboratories.
Div American Cyanamid Co
BCG Vaccine
Cholera Vaccine (strains 
Ogawa-lnaba)
Cholera Vaccine
Cholera Vaccine
Diphtheria Tetanus Toxoids 
Adsorbed (Purogenated for 
Pediatric Use)
M assachusetts Public 
Health Biol Labs
Diphtheria and Tetanus Toxoids 
Adsorbed
Biol Prods Program, 
Michigan Dept of 
Public Health
Sciavo  SpA*
Diphtheria and Tetanus Toxoids 
Adsorbed (Pediatric)®
Diphtheria and Tetanus Toxoids 
Adsorbed (For Pediatric Use)
Diphtheria and tetanus 
toxoids and pertussis 
vaccine adsorbed
W yeth Labs, Inc
Connaught Labs, Inc*
Diphtheria and Tetanus Toxoids 
Adsorbed ([pediatric] Aluminum 
Phosphate Adsorbed, Ultrafined)
Diphtheria and Tetanus Toxoids and 
Pertussis Vaccine Adsorbed
Lederle Laboratories,
Div American Cyanamid Co
M assachusetts Public 
Health Biol Labs
Diphtheria ano Tetanus Toxoids and 
Pertussis Vaccine Adsorbed 
(Tri Immunol®)
Diphtheria and Tetanus Toxoids and 
Pertussis Vaccine Adsorbed
'Available only to the U.S. Armed Forces.
*Connaught Laboratories, Inc., products distributed in the United States by E R. Squibb and Sons, Inc. 
Sciavo  S p A  products distributed in United States by Sciavo, Inc. Institut Merieux products distributed in 
United States by Merieux Institute, Inc.
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Immunobiologic M anufacturer Product Name
Diphtheria toxoid adsorbed
Biol Prods Program, 
Michigan Dept of 
Public Health
W yeth Labs, Inc
Sciavo S p A 1
Diphtheria and Tetanus Toxoids and 
Pertussis Vaccine A dsorbed■>
Diphtheria and Tetanus Toxoids and 
Pertussis Vaccine Adsorbed 
(Aluminum Phosphate Adsorbed, 
Ultrafined, Triple Antigen)
Diphtheria Toxoid Adsorbed 
(Pediatric)
Hepatitis B immune 
globulin
Alpha Therapeutic Corp 
Produces for 
Abbott Laboratories
Hepatitis B Immune Globulin 
(Human) (H-BIG®)
Merck Sharp & Dohme Div 
of Merck & Co, Inc
Hepatitis B Immune Globulin (Human) 
(MSD, HEP-B-GAM M EE®)
Hepatitis B vaccine 
Immune globulin
Cutter Biological Div 
of Miles Labs, Inc
Merck Sharp & Dohme Div 
of Merck & Co, Inc
Alpha Therapeutic Corp
Armour Pharmaceutical 
Co
Hepatitis B Immune Globulin 
(H YPER-H EP11)
Hepatitis B Vaccine (MSD, 
HEPTAVAX-B1")
Immune Serum Globulin (Human)
Immune Serum Globulin (Human) 
(GAMMAR«)
Central Laboratory Blood 
Transfusion Service, Sw iss  
Red Cross
Immune Globulin Intravenous 
(SA N D 0G L0BU LIN «)
Cutter Biological Div 
of Miles Labs. Inc
Immune Serum Globulin (Human) 
(G A M A STA N ‘‘ )
Immune Globulin Intravenous 
[5% in 10% Maltose (GAMIMUNE®)]
Hyland Therapeutics Div 
Travenol Labs, Inc 
also produces for 
Savage Labs
Immune Serum Globulin (Human)
Immune Serum Globulin (Human) 
(IMMUGLOBULIN4)
M assachusetts Public 
Health Biol Labs
Immune Serum Globulin (Human)
^Connaught Laboratories, Inc., products distributed in the United States by E. R Squibb and Sons, Inc. 
Sciavo  S p A  products distributed in United States by Sciavo, Inc. Institut Merieux products distributed in 
United States by Merieux Institute, Inc.
§,Outside of Michigan, available only to health departments.
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Imm unobiologic M anufacturer Product Name
Influenza vaccine
Biol Prods Program, 
Michigan Dept of 
Public Health
W yeth Labs, Inc
New York Blood Ctr, Inc
Connaught Labs, Inc^
Immune Serum Globulin (Human)
Immune Serum Globulin (Human)
Immune Serum Globulin (Human)
Influenza Virus Vaccine 
([Zonal Purified]), W hole Virion 
(FLUZONE®)
Influenza Virus Vaccine 
([Zonal Purified]), Split Virion 
(FLUZONE^)
Measles and mumps 
vaccine, live
Measles, mumps and rubella
vaccine
Measles and rubella vaccine
Measles vaccine
M eningococcal polysaccharide 
vaccine
A and C
A, C, Y, and W  135
Parke-Davis, Div of 
Warner-Lambert Co
Wyeth Labs, Inc
Merck Sharp & Dohme Div 
of Merck & Co, Inc
Merck Sharp & Dohme Div 
of Merck & Co, Inc
Merck Sharp & Dohme Div 
of Merck & Co, Inc
Merck Sharp & Dohme Div 
of Merck & Co, Inc
X
Connaught Labs, In c1
Connaught Labs, Inc^
Influenza Virus Vaccine 
(Split Virion [FLUOGEN®])
Influenza Virus Vaccine 
Trivalent Types A  and B 
(Chromatograph),
Subvirion Antigen
Measles and Mumps Virus Vaccine, 
Live (MSD, M-M-VAX®)
Measles, Mumps and Rubella 
Virus Vaccine, Live 
(MSD, MMR II»')
Measles and Rubella Virus 
Vaccine, Live 
(MSD, M -R-VAX II®)
Measles Virus Vaccine, Live 
(Attenuated [MSD,]
A TTEN U VA XH )
Meningococcal 
Polysaccharide Vaccine 
(MENOMUNE-A/C®’)
Meningococcal 
Polysaccaride Vaccine 
(M EN OM U NE-A/CY/W -1 3 5 ')
^Connaught Laboratories, Inc., products distributed in the United States by E. R. Squibb and Sons, Inc. 
Sciavo  S p A  products distributed in United States by Sciavo, Inc. Institut Merieux products distributed in 
United States by Merieux Institute, Inc.
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3 0 . 1 9 8 4 , b y  m a n u fa ctu re r  an d pro-
Immunobiologic M anufacturer Product Name
Mumps vaccine Merck Sharp & Dohme Div 
of Merck & Co, Inc
Mumps Virus Vaccine, Live 
(MSD, M UM PSVAX»)
Pertussis immune globulin Cutter Biological Div 
of Miles Labs, Inc
Pertussis Immune Globulin (Human) 
(H YP ER TU SSIS®)
Pertussis vaccine adsorbed Biol Prods Program, 
Michigan Dept of 
Public Health
Pertussis Vaccine Adsorbed
Plague vaccine Cutter Biological Div 
of Miles Labs, Inc
Plague Vaccine
Pneumococcal polysaccharide Lederle Laboratories,
Div American Cyanamid Co
Pneum ococcal Vaccine, Polyvalent 
(PNEU-IMUNE23 ,
Merck Sharp & Dohme Div 
of Merck & Co, Inc
Pneumococcal Vaccine, Polyvalent 
(MSD, PNEUMOVAX 23 )
Poliovirus vaccine 
Inactivated Connaught Labs, LtdT 
(Purified-Salk)
Poliomyelitis Vaccine
Oral Lederle Laboratories,
Div American Cyanamid Co
Poliovirus Vaccine, Live, Oral 
Trivalent (ORIMUNE I
Rabies immune globulin Cutter Biological Div 
of Miles Labs, Inc
Rabies Immune Globulin (Human) 
(HYPERAB )
Institut Merieux1 Rabies Immune Globulin (Human) 
(IMOG AMR ABIES'")
Rabies vaccine Institut Merieux 1 Rabies Vaccine
(Human Diploid Cell IIMOVAX '
Wyeth Labs, Inc Rabies Vaccine
(Human Diploid Cell Strain,
Subvirion Antigen [W YVAC ])
Rubella vaccine Merck Sharp & Dohme Div 
of Merck & Co, Inc
Rubella Virus Vaccine, Live 
(MSD, MERUVAX II)
Rubella and mumps vaccine Merck Sharp & Dohme Div
of Merck & Co, Inc
Rubella and Mumps Virus 
Vaccine, Live 
(MSD, BlAVAX^'II)
Tetanus immune globulin Alpha Therapeutic Corp Tetanus Immune Globulin (Human)
^Connaught Laboratories, Inc., products distributed in the United States by E. R. Squibb and Sons, Inc. 
Sciavo S p A  products distributed in United States by Sciavo, Inc. Institut Merieux products distributed in 
United States by Merieux Institute, Inc.
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A P P E N D IX  3. Im m u n o b io lo g ie s  a v a ila b le  a s  of Ju n e
d u c t  n a m e  — C o n tin u e d
3 0 . 1 9 8 4 , b y  m a n u fa ctu re r  and pro-
Imm unobiologic M anufacturer Product Name
Cutter Biological Div 
of Miles Labs. Inc
Tetanus Immune Globulin (Human) 
(H YPER-TET®)
Hyland Therapeutics Div 
Travenol Labs, Inc
Tetanus Immune Globulin (Human) 
(HU-TET®)
Hyland Therapeutics Div 
Travenol Labs, Inc 
also produces for 
Savage Labs
Tetanus Immune Globulin (Human) 
(HOM O-TET®)
Tetanus and diphtheria 
toxoids adsorbed
Wyeth Labs, Inc
M assachusetts Public 
Health Biol Labs
Connaught Labs, Inc^
Tetanus Immune Globulin (Human) 
Tetanus Immune Globulin (Human)
Tetanus and Diphtheria Toxoids 
Adsorbed (For Adult Use)
Lederle Laboratories,
Div American Cyanamid Co
Massachusetts Public 
Health Biol Labs
Tetanus and Diphtheria Toxoids 
Adsorbed (For Adult Use) 
(Purogenated Parenteral)
Tetanus and Diphtheria Toxoids 
Adsorbed (For Adult Use)
Biol Prods Program, 
Michigan Dept of 
Public Health
Tetanus and Diphtheria Toxoids 
Adsorbed (For Adult Use) (not 
available to health departments 
outside Michigan)
Sciavo  S p A ' Tetanus and Diphtheria Toxoids 
Adsorbed (For Adult Use)
Tetanus toxoid adsorbed
Wyeth Labs, Inc
Connaught Labs, lncT
Lederle Laboratories.
Div American Cyanamid Co
Tetanus and Diphtheria Toxoids 
Adsorbed (For Adult Use)
[Aluminum Phosphate, Ultrafined]
Tetanus Toxoid Adsorbed
Tetanus Toxoid Adsorbed 
(Purogenated [Aluminum Phosphate 
Adsorbed])
Massachusetts Public 
Health Biol Labs
Tetanus Toxo:d Adsorbed
^Connaught Laboratories, Inc., products distributed in the United States by E. R Squibb and Sons, Inc. 
Sciavo  S p A  products distributed in United States by Sciavo, Inc. Institut Merieux products distributed in 
United States by Merieux Institute, Inc.
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Im m unobiologic M anufacturer Product Name
Biol Prods Program, 
Michigan Dept of 
Public Health
Tetanus Toxoid Adsorbed
Sclavo  SpA * Tetanus Toxoid Adsorbed
Wyeth Labs, Inc Tetanus Toxoid Adsorbed 
(Aluminum Phosphate Adsorbed, 
Ultrafined)
Tetanus toxoid, fluid Connaught Labs, Inc* Tetanus Toxoid (Fluid)
Lederle Laboratories,
Div American Cyanamid Co
Tetanus Toxoid
(Purogenated, Tetanus Toxoid Fluid)
W yeth Labs, Inc Tetanus Toxoid
(Fluid, Purified, Ultrafined)
Typhoid vaccine Wyeth Labs, Inc Typhoid Vaccine^
Varicella-zoster immune 
globulin
M assachusetts Public 
Health Biol Labs
Varicella-Zoster Immune Globulin 
(Human)
Yellow fever vaccine Connaught Labs, Inc* Yellow Fever Vaccine 
(Live, 1 7D Virus, ALV-Free 
[YF-VAX®])
NOTE: In the preparation of this appendix every effort was made to assure its completeness and accura­
cy. Th is  appendix was compiled from information obtained from manufacturers, the Division of Product 
Certification, Food and Drug Administration, and the Physicians Desk Reference, 37th Edition, 1983, 
and to the best of our knowledge is an accurate and complete listing as of June 30, 1984 However, 
om issions and errors may have occurred inadvertently. This appendix is intended to be a resource and 
does not replace the provider's obligation to remain otherwise current on the availability of vaccines, 
toxoids, and immune globulins.
^Connaught Laboratories, Inc., products distributed in the United States by E. R. Squibb and Sons, Inc. 
Sclavo Sp A  products distributed in United States by Sclavo, Inc. Institut Merieux products distributed in 
United States by Merieux Institute, Inc.
The acetone-killed and -dried form of this vaccine is available only to the U.S. Armed Forces.
A P P EN D IX  4. Use of im m unobiologies in pregnancy*^
Im munizing
agent
Risk from 
disease to 
pregnant 
female
Risk from 
disease to 
fetus or 
neonate
Type of
im m unizing
agent
L IV E -V IR U S  V A CCIN ES
Measles Significant 
morbidity, low 
mortality; not 
altered by 
pregnancy
Significant 
increase in 
abortion rate; 
may cause 
malformations
Live, attenuated 
virus vaccine
Mumps Low morbidity 
and mortality; 
not altered by 
pregnancy
Probable 
increased rate 
of abortion in 
1 st trimester. 
Questionable 
association of 
fibroelastosis 
in neonates
Live, attenuated 
virus vaccine
Poliomyelitis No increased 
incidence in 
pregnancy, but 
may be more 
severe if it 
does occur
Anoxic fetal 
damage reported; 
50?, mortality in 
neonatal disease
Live, attenuated 
virus (OPV) and 
inactivated virus 
(IPV) vaccine®
Risk from Indications
im munizing for immunization
agent during Dose
to fetus pregnancy schedule Com m ents
None
confirmed
Contraindicated 
(See immune 
globulins)
Single dose Vaccination of 
susceptible 
women should be 
part of post­
partum care
None
confirmed
Contraindicated Single dose
None
confirmed
Not routinely 
recommended 
for adults in U.S.. 
except persons at 
increased risk of 
exposure
Primary: 3 doses 
of IPV at 4 -8  week 
intervals and a 
4th dose 6-12  
months after the 
3rd dose; 2 doses 
of OPV with a 6-8 
week interval and 
a 3rd dose at 
least 6 weeks 
later, customarily 
8-1 2 months later. 
Booster: Every 5 
years until 18 years 
of age for IPV
Vaccine indicated 
for susceptible 
pregnant women 
traveling in 
endemic areas 
or in other high­
risk situations
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Rubella Low morbidity 
and mortality; 
not altered by 
pregnancy
Yellow fever
High rate of 
abortion and 
congenital 
rubella 
syndrome
Unknown
TO X O ID S
Tetanus-
Diphtheria
Neonatal tetanus 
mortality 60%
Significant 
morbidity and 
mortality; not 
altered by 
pregnancy
Severe 
morbidity; 
tetanus 
mortality 60%, 
diphtheria 
mortality 10%; 
unaltered by 
pregnancy
IM M U N E G LO B U LIN S : H YPER IM M U N E
Hepatitis B Possible 
increased 
severity during 
3rd trimester
Possible 
increase in 
abortion rate 
and prematurity. 
Perinatal trans-
Live, attenuated 
virus vaccine
None
confirmed
Contraindicated Single dose
Live, attenuated 
virus vaccine
Combined
tetanus-
diphthena
toxoids
preferred; adult 
tetanus- 
diphtheria 
formulation
Hepatitis B 
immune globulin 
(HBIG) '
Unknown
None
confirmed
Contraindicated 
except if 
exposure 
unavoidable
Lack of primary 
series, or no 
booster within 
past 10 years
None reported Postexposure
prophylaxis
Single dose
Primary: 2 doses 
at 1 - to 2-month 
interval with a 
3rd dose 6-1 2 
months after the 
second; Booster: 
single dose every 
10 years, after 
completion of the 
primary series
0.06 ml/kg or 5 ml 
immediately, plus 
hepatitis B (HB) 
vaccine series, 
if indicated
Teratogenicity of 
vaccine is 
theoretical, not 
confirmed to 
date; vaccination 
of susceptible 
women should be 
part of post­
partum care
Postponement of 
travel preferable 
to vaccination, if 
possible
Updating of 
immune status 
should be part of 
antepartum care
Infants born to 
HBsAg-positive 
mothers should 
receive 0.5 ml 
HBIG as soon as
■Reproduced from: American College of Obstetrics and Gynecologists. Immunization during pregnancy (ACOG Technical Bulletin #64), Washington, D C. 
ACOG. May 1982.
f The Appendix, Immunization During Pregnancy, describes methods and techniques of clinical practice that are currently acceptable and used by recog­
nized authorities. However, it does not represent official policy or recommendations of the American College of Obstetricians and Gynecologists. Its publi­
cation should not be construed as excluding other acceptable methods of handling similar problems.
§IPV recommmended for unimmunized adults at increase risk.
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A P P EN D IX  4. Use of im m unobiologies in pregnancy- * — Continued
Im m unizing
agent
Risk from 
disease to 
pregnant 
female
Risk from 
disease to 
fetus or 
neonate
Type of
immunizing
agent
mission may occur 
if mother is a 
chronic carrier 
or is acutely 
infected
Rabies Near 100% 
fatality; not 
altered by 
pregnancy
Determined by 
maternal disease
Rabies immune 
globulin (RIG)
Tetanus Severe 
morbidity; 
mortality 60°,
Neonatal tetanus 
mortality 60%
Tetanus immune 
globulin (TIG)
Varicella Possible 
increase in 
severe 
varicella 
pneumonia
Can cause 
congenital 
varicella with 
increased 
mortality in 
neonatal period; 
very rarely 
causes 
congenital 
defects
Varicella-zoster 
immune globulin 
(VZIG) '
IN A CTIV A TED -V IRU S V A CCIN ES
Hepatitis B Possible Possible Inactivated
increased increase in HB vaccine
severity during abortion rate
3rd trimester and prematurity.
Risk from Indications
im m unizing for immunization
agent during Dose
to fetus pregnancy schedule Com m ents
possible after 
birth, plus 0.5 ml 
HB vaccine within 
1 week of birth. 
Vaccine should be 
repeated at 1 and 
6 months
None reported Postexposure 
prophylaxis
None reported Postexposure 
prophylaxis
20 lU/kg in one 
dose of RIG
250  units in one 
dose of TIG
Used in
conjunction with 
rabies killed- 
virus vaccine
Used in
conjunction with 
tetanus toxoid
None reported Not routinely 
indicated in 
healthy pregnant 
women exposed 
to varicella
1 vial/kg in one 
dose of VZIG, up 
to 5 vials
Only indicated 
for newborns of 
mothers who 
developed 
varicella within 
4 days prior to 
delivery or 2 days 
following delivery. 
Approximately 90%- 
95% of adults are 
immune to 
varicella
None reported Indications for 
prophylaxis not 
altered by 
pregnancy
1.0 ml (20 fig) IM 
at time, 0, 1, and 
6 months
Infants born to 
HBsAg-positive 
mothers should 
receive 0  5 ml
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Perinatal trans­
mission may occur 
if mother is a 
chronic carrier 
or is acutely 
infected
HBIG as soon as 
possible after 
birth, plus 0.5 ml 
HB vaccine within 
1 week of birth. 
Vaccine should be 
repeated at 1 and 
6 months
uu
Influenza
Rabies
Possible 
increase 
in morbidity 
and mortality
Possible 
increased 
abortion rate; 
no malformations
Inactivated 
type A and type B 
virus vaccines
None
confirmed
during epidemic confirmed
of new antigenic
strain
Near 100?: 
fatality; not 
altered by 
pregnancy
Determined 
by maternal 
disease
IN A CTIV A TED -B A CTER IA  V A CCIN ES
Cholera Significant 
morbidity and 
mortality; more 
severe during 
3rd trimester
Killed-virus
vaccine
Unknown
Increased risk 
of fetal death 
during 3rd 
trimester 
maternal illness
Killed-bacteria
vaccine
Unknown
Usually 
recommended 
only for patients 
with serious 
underlying 
diseases; public 
health authorities 
to be consulted 
for current 
recommendation
Indications for 
prophylaxis not 
altered by 
pregnancy;each 
case considered 
individually
Only to meet 
international 
travel
requirements
Consult with 
public health 
authorities since 
recommendations 
change each year
Public health 
authorities to be 
consulted for 
indications and 
dosage
2 injections, 4 -8  
weeks apart
Criteria for 
vaccination of 
pregnant women 
same as for all 
adults
Vaccine of low 
efficacy
£
3S3J
"Reproduced from: American College of Obstetrics and Gynecologists. Immunization during pregnancy (ACOG Technical Bulletin #64), Washington, D C. 
ACOG. May 1982.
fThe Appendix, Immunization During Pregnancy, describes methods and techniques of clinical practice that are currently acceptable and used by recog­
nized authorities. However, it does not represent official policy or recommendations of the American College of Obstetricians and Gynecologists. Its publi- o> 
cation should not be construed as excluding other acceptable methods of handling similar problems $
A P P EN D IX  4. Use of im m unobiologies in pregnancy** — Continued
Im munizing
agent
Risk from 
disease to 
pregnant 
female
Risk from 
disease to 
fetus or 
neonate
Type of
im m unizing
agent
Meningo­
coccus
No increased 
risk during 
pregnancy; no 
increase in 
severity of 
disease
Unknown Killed-bacteria
vaccine
Plague Significant 
morbidity and 
mortality; not 
altered by 
pregnancy
Determined by 
maternal disease
Killed-bacteria
vaccine
Pneumo­
coccus
No increased 
risk during 
pregnancy; no 
increase in 
severity of 
disease
Unknown Polyvalent
polysaccharide
vaccine
Typhoid Significant 
morbidity and 
mortality; not 
altered by 
pregnancy
Unknown Killed-bacteria
vaccine
Hepatitis A Possible 
increased 
severity during 
3rd trimester
Probable increase 
in abortion rate 
and prematurity. 
Possible
Pooled immune 
globulin (IG)
Risk from 
im m unizing 
agent 
to fetus
No data 
available on 
use during 
pregnancy
None reported
No data 
available on 
use during 
pregnancy
None
confirmed
None reported
Indications
for immunization
during Dose
pregnancy schedule Comm ents
Indications not 
altered by 
pregnancy; 
vaccination 
recommended 
only in unusual 
outbreak 
situations
Very selective 
vaccination of 
exposed persons
Indications not 
altered by 
pregnancy; 
vaccine used only 
for high-risk 
individuals
Not
recommended 
routinely except 
for close, 
continued 
exposure or travel 
to endemic areas
Postexposure
prophylaxis
Public health 
authorities to be 
consulted
Public health 
authorities to be 
consulted for 
indications and 
dosage
In adults 1 dose 
only
Primary; 2 
injections, 4 
weeks apart; 
Booster; single 
dose
0.02 ml/kg in 1 
dose of IG
IG should be 
given as soon as 
possible and 
within 2 weeks of
transmission to 
neonate at 
delivery if 
mother is 
incubating the 
virus or is 
acutely ill at 
that time
exposure. Infants 
born to mothers 
who are 
incubating the 
virus or are 
acutely ill at 
delivery should 
receive one dose 
of 0.5 ml as soon 
as possible after 
birth
u
SSz
Measles Significant 
morbidity, low 
mortality; not 
altered by 
pregnancy
Significant 
increase in 
abortion rate; 
may cause 
malformations
Pooled immune 
globulin (IG)
None reported Postexposure 
prophylaxis
0.25 ml/kg in 1 
dose of IG. up to 
1 5 ml
Unclear if it 
prevents 
abortion. Must 
be given within 
6 days of exposure
'Reproduced from: American College of Obstetrics and Gynecologists. Immunization during pregnancy (ACOG Technical Bulletin #64), Washington, D C. 
ACOG. May 1982. |
f The Appendix, Immunization During Pregnancy, describes methods and techniques of clinical practice that are currently acceptable and used by recog- g
nized authorities. However, it does not represent official policy or recommendations of the American College of Obstetricians and Gynecologists. Its publi- 31
cation should not be construed as excluding other acceptable methods of handling similar problems.
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Service  area
Regional center 
and 24-hour telephone Service  area
Regional center 
and 24-hour telephone
M assachusetts
Maine
Connecticut
Vermont,
New Hampshire
Rhode Island
New Jersey, 
New York
New York
M assachusetts Public Health 
Biologies Laboratories 
305 South St.
Jam aica Plain, MA 0 2 1 3 0  
(617) 5 2 2 -3 7 0 0
American Red Cross 
Blood Services 
Northeast Region 
81 2 Huntington Ave.
Boston, MA 0211 5 
(617) 7 3 1 -2 1 3 0
American Red Cross 
Blood Services 
Northeast Region­
Portland Location 
524  Forest Ave.
Portland, ME 04101 
(207) 7 7 5 -2 3 6 7
American Red Cross 
Blood Services 
Connecticut Region 
209 Farmington Ave. 
Farmington, C T  0 6032  
(203) 6 7 8 -2 7 3 0
American Red Cross 
Blood Services 
Vermont-New Hampshire 
Region 
32 N. Prospect St.
Burlington, V T  0 5402  
(802) 6 5 8 -6 4 0 0
Rhode Island Blood Center 
551 N. Main St.
Providence, Rl 0 2 9 0 4  
(401) 8 6 3 -8 3 6 8
The Greater New York 
Blood Program 
1 50 Amsterdam Ave.
New York, NY 10023 
(212) 5 7 0 -3 0 6 7  
(212) 5 7 0 -3 0 6 8  (night)
American Red Cross 
Blood Services
Northeastern New York Region 
Hackett Blvd. at 
Clara Barton Dr.
Albany, NY 12208 
(518) 4 4 9 -5 0 2 0  
(518) 462-7461  
(518) 4 6 2 -6 9 6 4  (night)
American Red Cross 
Blood Services 
Greater Buffalo Chapter 
786 Delaware Ave.
Buffalo, NY 14209 
(716) 8 8 6 -7 5 0 0
American Red Cross 
Blood Services 
Rochester Region 
50 Prince St.
Rochester, NY 14607 
(716) 4 6 1 -9 8 0 0
American Red Cross 
Blood Services 
Syracuse Region 
636  S. Warren St. 
Syracuse, NY 1 3202 
(315) 4 2 5 -1 6 4 7
American Red Cross 
Blood Services 
Penn-Jersey Region 
23rd and Chestnut 
Philadelphia, PA 19103 
(215) 2 9 9 -4 1 1 0
American Red Cross 
Blood Services 
Baltimore Region 
2701 N. Charles St. 
Baltimore, MD 21218  
(301) 4 6 7 -9 9 0 5
American Red Cross 
Blood Services 
Tidewater Region 
61 1 W. Brambleton Ave. 
P.O. Box 1836 
Norfolk, VA 23501 
(804) 4 4 6 -7 7 0 8
Richmond Metropolitan 
Blood Service 
2201 W estwood Ave. 
Richmond, VA 2 3230  
(804) 3 5 9 -5 1 0 0
Washington, D C., American Red Cross 
Maryland, Virginia, Blood Services 
W est Virginia Washington Region 
2025 E Street, N.W 
W ashington, DC 20006  
(202) 7 2 8 -6 4 2 6
American Red Cross
Blood Services
Tri-State Region
1111 Veterans Memorial Blvd
F.O. Box 605
Huntington, W V  2 5 7 1 0
(304) 5 2 2 -0 3 2 8
Delaware, 
Pennsylvania, 
Southern 
New Jersey
Maryland
Virginia
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S e rv ice  area
Regional center 
and 24-hour telephone Service  area
Regional center 
and 24-hour telephone
Georgia American Red Cross 
Blood Services 
Atlanta Region 
1 925 Monroe Dr., N.E. 
Atlanta. GA 30324  
(404) 8 8 1 -9 8 0 0  
(404) 8 8 1 -6 7 5 2  (night)
American Red Cross 
Blood Services 
Wolverine Region 
202 E. Boulevard Dr. 
Flint. Ml 48501 
(313) 232-1 176
American Red Cross
North Carolina American Red Cross 
Blood Services 
Carolinas Region 
2425 Park Rd. 
Charlotte. NC 28236 
(704) 376-1661
Ohio
Blood Services 
Great Lakes Region 
1 800  E. Grand River 
Lansing, Ml 4891 2 
(517) 484-7461
American Red Cross
South Carolina American Red Cross 
Blood Services 
South Carolina Region 
1100 Shirley St. 
Columbia, S C  29205 
(803) 256-2301
Blood Services 
Northern Ohio Region 
395 0  Chester Ave. 
Cleveland, OH 441 14 
(216) 7 8 1 -1 8 0 0
American Red Cross
Florida South Florida 
Blood Service 
1675 N.W. Ninth Ave. 
Miami, FL 331 36 
(305) 3 2 6 -8 8 8 8
W isconsin, Iowa,
Central Ohio Region 
995 E. Broad St. 
Columbus, OH 4 3 2 0 5  
(614) 253-7981
The Blood Center of
American Red Cross North Dakota, S.E  W isconsin
Blood Services 
Mid-Florida Region 
341 W hiteSt.
Daytona Beach, FL 3 2 0 1 4
South Dakota 1 701 W. W isconsin Ave. 
Milwaukee, W l 53233  
(414) 9 3 3 -5 0 0 0
(904) 2 5 5 -5 4 4 4 W isconsin American Red Cross 
Blood Services
Alabama, American Red Cross Badger Region
M ississippi Blood Services 
Alabama Region 
2225  Third Ave., N. 
Birmingham, A L  35203
1202 Ann St. 
Madison, W l 53713  
(608) 255-0021
(205) 322-5661 Minnesota American Red Cross 
Blood Services
Indiana American Red Cross 
Blood Services 
Fort Wayne Region 
1 212 E. California Rd. 
Fort Wayne, IN 4 6825  
(219) 482-3781
Northern Illinois
St. Paul Region 
100 S. Robert St.
St. Paul, MN 55107 
(612) 2 9 1 -6 7 8 9  
(612) 2 9 1 -6 7 6 7  (night)
American Red Cross
Michigan American Red Cross 
Blood Services
Southeastern Michigan Region 
100 Mack Ave.
P.O. Box 351 
Detroit, Ml 4 8 2 3 2  
(313) 4 9 4 -2 7 1 5
(Chicago) Blood Services 
Mid-America Region 
43  E. Ohio St. ' 
Chicago, IL 60611 
(312) 4 4 0 -2 2 2 2
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Serv ice  area
Regional center 
and 24-hour telephone S ervice  area
Regional center 
and 24-hour telephone
Arkansas, American Red Cross
Kansas, Kentucky, Blood Services
Missouri, 
Southern Illinois
Nebraska
Tennessee
Louisiana,
Oklahoma,
Texas
Colorado, 
New Mexico
Arizona
Hawaii,
Southern
California
Missouri-lllinois Region 
4 0 5 0  Lindell Blvd.
St. Louis, MO 63108 
(314) 6 5 8 -2 0 0 0  
(314) 6 5 8 -2 1 3 6  (night)
American Red Cross 
Blood Services 
Midwest Region 
3838 Dewey Ave.
Omaha, NE 68105 
(402) 3 4 1 -2 7 2 3
American Red Cross 
Blood Services 
Nashville Region 
321 22nd Ave., N.
Nashville, TN 3 7203  
(615) 3 2 7 -1 9 3 1 , ext. 315
Gulf Coast Regional 
Blood Center 
1400 La Concha 
Houston, T X  77054-1 802 
(713) 7 9 1 -6 2 5 0
American Red Cross 
Blood Services 
Central Texas Region 
McLennan County Chapter 
42 2 4  Cobbs Dr.
Waco, T X  7 6710  
(817) 7 7 6 -8 7 5 4
American Red Cross 
Blood Services 
Red River Region 
1809 Fifth St.
W ichita Falls, T X  76301 
(817) 3 2 2 -8 6 8 6
United Blood Services 
1515 University Blvd., N.E. 
P.O. Box 25445 
Albuquerque, NM 871 25 
(505) 247-9831
American Red Cross 
Blood Services 
Southern Arizona Region 
222 South Cherry Ave. 
Tucson, A Z  8571 9 
(602) 623-0541
American Red Cross 
Blood Services 
L A  -Orange Counties Region 
1 1 30  S. Vermont Ave.
Los Angeles, C A  9 0006  
(213) 7 3 9 -5 2 0 0
Nevada, Utah, 
W yoming, 
Northern 
California
Alaska, Montana, 
Oregon
Idaho
Washington
Canada
American Red Cross 
Blood Services 
Central California Region 
333 McKendrie St.
San Jose, C A  951 1 0 
(408) 2 9 2 -1 6 2 6
American Red Cross 
Blood Services 
Pacific Northwest Region 
4 2 0 0  S.W . Corbett St. 
Portland, OR 97201 
(503) 2 4 3 -5 2 8 6
American Red Cross 
Blood Services 
Snake River Region 
5380 Franklin St.
Boise, ID 83705 
(208) 3 4 2 -4 5 0 0
Puget Sound Blood Center 
Terry at Madison 
Seattle, WA 9 8 1 0 4  
(206) 2 9 2 -6 5 2 5
Canadian Red Cross 
Blood Transfusion Service 
National Office 
95 Wellesley St. E.
Toronto, Ontario M 4Y IH6 
(416) 9 2 3 -6 6 9 2
American Red Cross 
Servicio de Sangre Capitulo 
GPO Box 6046 
San Juan, PR 0 0 9 3 6  
(809) 7 5 9 -7 9 7 9
South Florida Community 
Blood Center 
1675 N.W. Ninth Ave. 
Miami, FL 33142 
(305) 3 2 6 -8 8 8 8
All other countries American Red Cross 
Blood Services 
Northeast Region 
60 Kendrick St. 
Needham, MA 021 94 
(617) 4 4 9 -0 7 7 3
American Red Cross 
Blood Services 
81 2 Huntington Ave. 
Boston, MA 021 1 5 
(617) 7 3 1 -2 1 3 0
Puerto Rico
Central and 
South America
1 6 R 0 7 3 0 9 8 4 0 3
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